1
|
Pastor Y, Reynard O, Iampietro M, Surenaud M, Picard F, El Jahrani N, Lefebvre C, Hammoudi A, Dupaty L, Brisebard É, Reynard S, Moureaux É, Moroso M, Durand S, Gonzalez C, Amurri L, Gallouët AS, Marlin R, Baize S, Chevillard E, Raoul H, Hocini H, Centlivre M, Thiébaut R, Horvat B, Godot V, Lévy Y, Cardinaud S. A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease. Cell Rep Med 2024; 5:101467. [PMID: 38471503 PMCID: PMC10983108 DOI: 10.1016/j.xcrm.2024.101467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 12/23/2023] [Accepted: 02/16/2024] [Indexed: 03/14/2024]
Abstract
Nipah virus (NiV) has been recently ranked by the World Health Organization as being among the top eight emerging pathogens likely to cause major epidemics, whereas no therapeutics or vaccines have yet been approved. We report a method to deliver immunogenic epitopes from NiV through the targeting of the CD40 receptor of antigen-presenting cells by fusing a selected humanized anti-CD40 monoclonal antibody to the Nipah glycoprotein with conserved NiV fusion and nucleocapsid peptides. In the African green monkey model, CD40.NiV induces specific immunoglobulin A (IgA) and IgG as well as cross-neutralizing responses against circulating NiV strains and Hendra virus and T cell responses. Challenge experiments using a NiV-B strain demonstrate the high protective efficacy of the vaccine, with all vaccinated animals surviving and showing no significant clinical signs or virus replication, suggesting that the CD40.NiV vaccine conferred sterilizing immunity. Overall, results obtained with the CD40.NiV vaccine are highly promising in terms of the breadth and efficacy against NiV.
Collapse
Affiliation(s)
- Yadira Pastor
- INSERM U955 - Équipe 16, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France; Vaccine Research Institute (VRI), Créteil, France
| | - Olivier Reynard
- Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Mathieu Iampietro
- Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Mathieu Surenaud
- INSERM U955 - Équipe 16, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France; Vaccine Research Institute (VRI), Créteil, France
| | - Florence Picard
- INSERM U955 - Équipe 16, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France; Vaccine Research Institute (VRI), Créteil, France
| | - Nora El Jahrani
- INSERM U955 - Équipe 16, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France; Vaccine Research Institute (VRI), Créteil, France
| | - Cécile Lefebvre
- INSERM U955 - Équipe 16, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France; Vaccine Research Institute (VRI), Créteil, France
| | - Adele Hammoudi
- INSERM U955 - Équipe 16, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France; Vaccine Research Institute (VRI), Créteil, France
| | - Léa Dupaty
- INSERM U955 - Équipe 16, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France; Vaccine Research Institute (VRI), Créteil, France
| | | | - Stéphanie Reynard
- Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France; Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, Université Paris Cité, Paris, France
| | | | - Marie Moroso
- Laboratoire P4 Inserm Jean Mérieux, Lyon, France
| | - Stéphanie Durand
- Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Claudia Gonzalez
- Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Lucia Amurri
- Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Anne-Sophie Gallouët
- Université Paris-Saclay, Inserm, CEA, Immunologie des maladies virales, autoimmunes, hématologiques et bactériennes (IMVA-HB/IDMIT/UMR1184), Fontenay-aux-Roses, France
| | - Romain Marlin
- Université Paris-Saclay, Inserm, CEA, Immunologie des maladies virales, autoimmunes, hématologiques et bactériennes (IMVA-HB/IDMIT/UMR1184), Fontenay-aux-Roses, France
| | - Sylvain Baize
- Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France; Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, Université Paris Cité, Paris, France
| | | | - Hervé Raoul
- Laboratoire P4 Inserm Jean Mérieux, Lyon, France
| | - Hakim Hocini
- INSERM U955 - Équipe 16, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France; Vaccine Research Institute (VRI), Créteil, France
| | - Mireille Centlivre
- INSERM U955 - Équipe 16, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France; Vaccine Research Institute (VRI), Créteil, France
| | - Rodolphe Thiébaut
- Vaccine Research Institute (VRI), Créteil, France; University Bordeaux, Department of Public Health, INSERM Bordeaux Population Health Research Centre, Inria SISTM, Bordeaux, France; CHU Bordeaux, Department of Medical Information, Bordeaux, France
| | - Branka Horvat
- Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France
| | - Véronique Godot
- INSERM U955 - Équipe 16, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France; Vaccine Research Institute (VRI), Créteil, France
| | - Yves Lévy
- INSERM U955 - Équipe 16, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France; Vaccine Research Institute (VRI), Créteil, France; Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Créteil, France.
| | - Sylvain Cardinaud
- INSERM U955 - Équipe 16, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France; Vaccine Research Institute (VRI), Créteil, France.
| |
Collapse
|
2
|
Lafoux B, Baillet N, Picard C, Fourcaud G, Borges-Cardoso V, Reynard S, Journeaux A, Germain C, Perthame E, Mateo M, Hortion J, Carnec X, Pietrosemoli N, Moroso M, Lacroix O, Jourjon O, Barron S, Vallve A, Duthey A, Jacquot F, Barrot L, Dirheimer M, Raoul H, Nougier C, Baize S. Hemostasis defects underlying the hemorrhagic syndrome caused by mammarenaviruses in a cynomolgus macaque model. Blood 2023; 142:2092-2104. [PMID: 37699247 DOI: 10.1182/blood.2023020351] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 07/18/2023] [Accepted: 08/15/2023] [Indexed: 09/14/2023] Open
Abstract
Viral hemorrhagic fevers (HF) are a group of acute febrile diseases with high mortality rates. Although hemostatic dysfunction appears to be a major determinant of the severity of the disease, it is still unclear what pathogenic mechanisms lead to it. In clinical studies it is found that arenaviruses, such as Lassa, Machupo, and Guanarito viruses cause HF that vary in symptoms and biological alterations. In this study we aimed to characterize the hemostatic dysfunction induced by arenaviral HF to determine its implication in the severity of the disease and to elucidate the origin of this syndrome. We found that lethal infection with Machupo, Guanarito, and Lassa viruses is associated with cutaneomucosal, cerebral, digestive, and pulmonary hemorrhages. The affected animals developed a severe alteration of the coagulation system, which was concomitant with acute hepatitis, minor deficit of hepatic factor synthesis, presence of a plasmatic inhibitor of coagulation, and dysfunction of the fibrinolytic system. Despite signs of increased vascular permeability, endothelial cell infection was not a determinant factor of the hemorrhagic syndrome. There were also alterations of the primary hemostasis during lethal infection, with moderate to severe thrombocytopenia and platelet dysfunction. Finally, we show that lethal infection is accompanied by a reduced hematopoietic potential of the bone marrow. This study provides an unprecedented characterization of the hemostasis defects induced by several highly pathogenic arenaviruses.
Collapse
Affiliation(s)
- Blaise Lafoux
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Nicolas Baillet
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Caroline Picard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Gustave Fourcaud
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Virginie Borges-Cardoso
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Stéphanie Reynard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Alexandra Journeaux
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Clara Germain
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Emeline Perthame
- Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Paris, France
| | - Mathieu Mateo
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Jimmy Hortion
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Xavier Carnec
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| | - Natalia Pietrosemoli
- Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Paris, France
| | - Marie Moroso
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Orianne Lacroix
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Ophélie Jourjon
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Stéphane Barron
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Audrey Vallve
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Aurélie Duthey
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | | | - Laura Barrot
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Manon Dirheimer
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Hervé Raoul
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, Lyon, France
| | - Christophe Nougier
- Service d'hématologie Biologique, Centre de Pathologie et Biologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
| | - Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- Centre International de Recherche en Infectiologie, Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique UMR5308, Lyon, France
| |
Collapse
|
3
|
Garbuglia AR, Lapa D, Pauciullo S, Raoul H, Pannetier D. Nipah Virus: An Overview of the Current Status of Diagnostics and Their Role in Preparedness in Endemic Countries. Viruses 2023; 15:2062. [PMID: 37896839 PMCID: PMC10612039 DOI: 10.3390/v15102062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 10/02/2023] [Accepted: 10/05/2023] [Indexed: 10/29/2023] Open
Abstract
Nipah virus (NiV) is a paramyxovirus responsible for a high mortality rate zoonosis. As a result, it has been included in the list of Blueprint priority pathogens. Bats are the main reservoirs of the virus, and different clinical courses have been described in humans. The Bangladesh strain (NiV-B) is often associated with severe respiratory disease, whereas the Malaysian strain (NiV-M) is often associated with severe encephalitis. An early diagnosis of NiV infection is crucial to limit the outbreak and to provide appropriate care to the patient. Due to high specificity and sensitivity, qRT-PCR is currently considered to be the optimum method in acute NiV infection assessment. Nasal swabs, cerebrospinal fluid, urine, and blood are used for RT-PCR testing. N gene represents the main target used in molecular assays. Different sensitivities have been observed depending on the platform used: real-time PCR showed a sensitivity of about 103 equivalent copies/reaction, SYBRGREEN technology's sensitivity was about 20 equivalent copies/reaction, and in multiple pathogen card arrays, the lowest limit of detection (LOD) was estimated to be 54 equivalent copies/reaction. An international standard for NiV is yet to be established, making it difficult to compare the sensitivity of the different methods. Serological assays are for the most part used in seroprevalence studies owing to their lower sensitivity in acute infection. Due to the high epidemic and pandemic potential of this virus, the diagnosis of NiV should be included in a more global One Health approach to improve surveillance and preparedness for the benefit of public health. Some steps need to be conducted in the diagnostic field in order to become more efficient in epidemic management, such as development of point-of-care (PoC) assays for the rapid diagnosis of NiV.
Collapse
Affiliation(s)
- Anna Rosa Garbuglia
- Laboratory of Virology, National Institute for Infectious Diseases “Lazzaro Spallanzani” (IRCCS), 00149 Rome, Italy; (D.L.); (S.P.)
| | - Daniele Lapa
- Laboratory of Virology, National Institute for Infectious Diseases “Lazzaro Spallanzani” (IRCCS), 00149 Rome, Italy; (D.L.); (S.P.)
| | - Silvia Pauciullo
- Laboratory of Virology, National Institute for Infectious Diseases “Lazzaro Spallanzani” (IRCCS), 00149 Rome, Italy; (D.L.); (S.P.)
| | - Hervé Raoul
- French National Agency for Research on AIDS—Emerging Infectious Diseases (ANRS MIE), Maladies Infectieuses Émergentes, 75015 Paris, France;
| | - Delphine Pannetier
- Institut National de la Santé et de la Recherche Médicale, Jean Mérieux BSL4 Laboratory, 69002 Lyon, France;
| |
Collapse
|
4
|
Piorkowski G, Ghosn J, Coppée R, Mailhé M, Ferré VM, Houhou-Fidouh N, Yazdanpanah Y, Le Hingrat Q, Raoul H, Charpentier C, Descamps D, de Lamballerie X. Genomic diversity of mpox virus in Paris area (France) during the 2022 outbreak. J Med Virol 2023; 95:e28853. [PMID: 37288615 DOI: 10.1002/jmv.28853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Revised: 05/25/2023] [Accepted: 05/26/2023] [Indexed: 06/09/2023]
Abstract
In May 2022, several countries reported mpox cases from patients without history of traveling to endemic areas. France was one of the most affected European countries by this outbreak. In this study, the clinical characteristics of mpox cases in France were described, and the genetic diversity of the virus was studied. Patients diagnosed with mpox infection (quantitative polymerase chain reaction ct < 28) between May 21, and July 4, 2022 and between 16th August and 10th September 2022 were included to this study. Twelve amplicons corresponding to the most polymorphic regions of the mpox genome and covering ~30 000 nucleotides were generated and sequenced using the S5 XL Ion Torrent technology to evaluate the genetic diversity of mpox sequences. One hundred and forty-eight patients were diagnosed with mpox-infection. 95% were men, 5% transgender (M-to-F), 50% were taking human immunodeficiency virus (HIV) pre-exposure prophylaxis, and 25% were HIV seropositive. One hundred and sixty-two samples (some patients had two samples) were sequenced and compared to GenBank sequences. Overall, low genetic diversity of mpox sequences was found compared with pre-epidemic Western-African sequences, with 32 distinct mutational patterns. This study provides a first glance at the mutational landscape of early mpox 2022 circulating strains in Paris (France).
Collapse
Affiliation(s)
- Géraldine Piorkowski
- Unité des Virus Émergents (UVE: Aix-Marseille Université-IRD_190-Inserm_1207), Marseille, France
| | - Jade Ghosn
- Inserm, UMR1137, IAME, Service des Maladies Infectieuses et Tropicales, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, Paris, France
| | - Romain Coppée
- Inserm, UMR1137, IAME, Service de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, Paris, France
| | - Morgane Mailhé
- Inserm, UMR1137, IAME, Service des Maladies Infectieuses et Tropicales, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, Paris, France
| | - Valentine Marie Ferré
- Inserm, UMR1137, IAME, Service de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, Paris, France
| | - Nadhira Houhou-Fidouh
- Inserm, UMR1137, IAME, Service de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, Paris, France
| | - Yazdan Yazdanpanah
- Inserm, UMR1137, IAME, Service des Maladies Infectieuses et Tropicales, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, Paris, France
- Agence nationale de Recherche sur le SIDA et les hépatites virales, Maladies Infectieuses émergentes, Paris, France
| | - Quentin Le Hingrat
- Inserm, UMR1137, IAME, Service de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, Paris, France
| | - Hervé Raoul
- Agence nationale de Recherche sur le SIDA et les hépatites virales, Maladies Infectieuses émergentes, Paris, France
| | - Charlotte Charpentier
- Inserm, UMR1137, IAME, Service de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, Paris, France
| | - Diane Descamps
- Inserm, UMR1137, IAME, Service de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, Paris, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE: Aix-Marseille Université-IRD_190-Inserm_1207), Marseille, France
| |
Collapse
|
5
|
Mateo M, Reynard S, Pietrosemoli N, Perthame E, Journeaux A, Noy K, Germain C, Carnec X, Picard C, Borges-Cardoso V, Hortion J, Lopez-Maestre H, Regnard P, Fellmann L, Vallve A, Barron S, Jourjon O, Lacroix O, Duthey A, Dirheimer M, Daniau M, Legras-Lachuer C, Carbonnelle C, Raoul H, Tangy F, Baize S. Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys. Nat Commun 2023; 14:1352. [PMID: 36906645 PMCID: PMC10008018 DOI: 10.1038/s41467-023-37050-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Accepted: 02/22/2023] [Indexed: 03/13/2023] Open
Abstract
Lassa fever hits West African countries annually in the absence of licensed vaccine to limit the burden of this viral hemorrhagic fever. We previously developed MeV-NP, a single-shot vaccine protecting cynomolgus monkeys against divergent strains one month or more than a year before Lassa virus infection. Given the limited dissemination area during outbreaks and the risk of nosocomial transmission, a vaccine inducing rapid protection could be useful to protect exposed people during outbreaks in the absence of preventive vaccination. Here, we test whether the time to protection can be reduced after immunization by challenging measles virus pre-immune male cynomolgus monkeys sixteen or eight days after a single shot of MeV-NP. None of the immunized monkeys develop disease and they rapidly control viral replication. Animals immunized eight days before the challenge are the best controllers, producing a strong CD8 T-cell response against the viral glycoprotein. A group of animals was also vaccinated one hour after the challenge, but was not protected and succumbed to the disease as the control animals. This study demonstrates that MeV-NP can induce a rapid protective immune response against Lassa fever in the presence of MeV pre-existing immunity but can likely not be used as therapeutic vaccine.
Collapse
Affiliation(s)
- Mathieu Mateo
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007, Lyon, France
| | - Stéphanie Reynard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007, Lyon, France
| | - Natalia Pietrosemoli
- Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Paris, France
| | - Emeline Perthame
- Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Paris, France
| | - Alexandra Journeaux
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007, Lyon, France
| | - Kodie Noy
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007, Lyon, France
| | - Clara Germain
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007, Lyon, France
| | - Xavier Carnec
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007, Lyon, France
| | - Caroline Picard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007, Lyon, France
| | - Virginie Borges-Cardoso
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007, Lyon, France
| | - Jimmy Hortion
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007, Lyon, France
| | - Hélène Lopez-Maestre
- Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Paris, France
| | - Pierrick Regnard
- SILABE, Université de Strasbourg, fort Foch, Niederhausbergen, France
| | - Lyne Fellmann
- SILABE, Université de Strasbourg, fort Foch, Niederhausbergen, France
| | - Audrey Vallve
- Laboratoire P4 INSERM - Jean Mérieux, INSERM US003, 69007, Lyon, France
| | - Stéphane Barron
- Laboratoire P4 INSERM - Jean Mérieux, INSERM US003, 69007, Lyon, France
| | - Ophélie Jourjon
- Laboratoire P4 INSERM - Jean Mérieux, INSERM US003, 69007, Lyon, France
| | - Orianne Lacroix
- Laboratoire P4 INSERM - Jean Mérieux, INSERM US003, 69007, Lyon, France
| | - Aurélie Duthey
- Laboratoire P4 INSERM - Jean Mérieux, INSERM US003, 69007, Lyon, France
| | - Manon Dirheimer
- INSERM, Délégation Régionale Auvergne Rhône-Alpes, 69500, Bron, France
| | | | | | | | - Hervé Raoul
- Laboratoire P4 INSERM - Jean Mérieux, INSERM US003, 69007, Lyon, France
| | - Frédéric Tangy
- Vaccine Innovation Laboratory, Institut Pasteur, 75015, Paris, France
| | - Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007, Lyon, France. .,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007, Lyon, France.
| |
Collapse
|
6
|
Lebarbenchon C, Goodman SM, Hoarau AOG, Le Minter G, Dos Santos A, Schoeman MC, Léculier C, Raoul H, Gudo ES, Mavingui P. Bombali Ebolavirus in Mops condylurus Bats (Molossidae), Mozambique. Emerg Infect Dis 2022; 28:2583-2585. [PMID: 36418002 PMCID: PMC9707587 DOI: 10.3201/eid2812.220853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
We detected Bombali ebolavirus RNA in 3 free-tailed bats (Mops condylurus, Molossidae) in Mozambique. Sequencing of the large protein gene revealed 98% identity with viruses previously detected in Sierra Leone, Kenya, and Guinea. Our findings further support the suspected role of Mops condylurus bats in maintaining Bombali ebolavirus.
Collapse
|
7
|
Li T, Cai H, Yao H, Zhou B, Zhang N, van Vlissingen MF, Kuiken T, Han W, GeurtsvanKessel CH, Gong Y, Zhao Y, Shen Q, Qin W, Tian XX, Peng C, Lai Y, Wang Y, Hutter CAJ, Kuo SM, Bao J, Liu C, Wang Y, Richard AS, Raoul H, Lan J, Seeger MA, Cong Y, Rockx B, Wong G, Bi Y, Lavillette D, Li D. Author Correction: A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. Nat Commun 2022; 13:4359. [PMID: 35896553 PMCID: PMC9329378 DOI: 10.1038/s41467-022-32074-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Tingting Li
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
| | - Hongmin Cai
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
| | - Hebang Yao
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
| | - Bingjie Zhou
- University of CAS, Beijing, China.,CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China
| | - Ning Zhang
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), CAS, Beijing, China
| | - Martje Fentener van Vlissingen
- Erasmus Laboratory Animal Science Center, Erasmus University Medical Center, Rotterdam, Netherlands.,European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France
| | - Thijs Kuiken
- European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France.,Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Wenyu Han
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.,University of CAS, Beijing, China
| | - Corine H GeurtsvanKessel
- European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France.,Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Yuhuan Gong
- University of CAS, Beijing, China.,CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), CAS, Beijing, China
| | - Yapei Zhao
- University of CAS, Beijing, China.,CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China
| | - Quan Shen
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), CAS, Beijing, China
| | - Wenming Qin
- National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute (Zhangjiang Laboratory), CAS, Shanghai, China
| | - Xiao-Xu Tian
- National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute (Zhangjiang Laboratory), CAS, Shanghai, China
| | - Chao Peng
- National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute (Zhangjiang Laboratory), CAS, Shanghai, China
| | - Yanling Lai
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.,University of CAS, Beijing, China
| | - Yanxing Wang
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
| | - Cedric A J Hutter
- Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
| | - Shu-Ming Kuo
- CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China
| | - Juan Bao
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
| | - Caixuan Liu
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.,University of CAS, Beijing, China
| | - Yifan Wang
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.,University of CAS, Beijing, China
| | - Audrey S Richard
- European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France
| | - Hervé Raoul
- European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France
| | - Jiaming Lan
- CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China
| | - Markus A Seeger
- Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
| | - Yao Cong
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
| | - Barry Rockx
- European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France.,Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Gary Wong
- CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China. .,Département de microbiologie-infectiologie et d'immunologie, Université Laval, Québec, QC, Canada.
| | - Yuhai Bi
- University of CAS, Beijing, China. .,CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), CAS, Beijing, China.
| | - Dimitri Lavillette
- CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China. .,Pasteurien College, Soochow University, Jiangsu, China.
| | - Dianfan Li
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.
| |
Collapse
|
8
|
Raoul H, Yazdanpanah Y. [Fighting infectious diseases: A never-ended renewed challenge]. Med Sci (Paris) 2022; 38:335-336. [PMID: 35485889 DOI: 10.1051/medsci/2022056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Hervé Raoul
- ANRS-Maladies infectieuses émergentes, Paris, France et Laboratoire P4 Inserm Jean Mérieux, Lyon, France
| | | |
Collapse
|
9
|
Mateo M, Hortion J, Perthame E, Picard C, Reynard S, Journeaux A, Germain C, Carnec X, Baillet N, Borges-Cardoso V, Pietrosemoli N, Vallve A, Barron S, Jourjon O, Lacroix O, Duthey A, Dirheimer M, Daniau M, Legras-Lachuer C, Jouvion G, Carbonnelle C, Raoul H, Baize S. Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys. Virulence 2022; 13:654-669. [PMID: 35437094 PMCID: PMC9037461 DOI: 10.1080/21505594.2022.2060170] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
The area of Lassa virus (LASV) circulation is expanding, with the emergence of highly pathogenic new LASV lineages. Benin recently became an endemic country for LASV and has seen the emergence of a new LASV lineage (VII). The first two outbreaks in 2014 and 2016 showed a relatively high mortality rate compared to other outbreaks. We infected cynomolgus monkeys with two strains belonging to lineage II and lineage VII that were isolated from deceased patients during the 2016 outbreak in Benin. The lineage VII strain (L7) caused uniform mortality. Death was associated with uncontrolled viral replication, unbalanced inflammatory responses characterized by increased concentrations of pro- and anti-inflammatory mediators, and the absence of efficient immune responses, resembling the pathogenesis associated with the prototypic Josiah strain in monkeys. The lineage II strain (L2) showed apparently lower virulence than its counterpart, with a prolonged time to death and a lower mortality rate. Prolonged survival was associated with better control of viral replication, a moderate inflammatory response, and efficient T-cell responses. Transcriptomic analyses also highlighted important differences in the immune responses associated with the outcome. Both strains caused strong inflammation in several organs. Notably, meningitis and encephalitis were observed in the cerebral cortex and cerebellum in all monkeys, independently of the outcome. Due to their apparently high pathogenicity, emerging strains from lineage VII should be considered in preclinical vaccine testing. Lineage II would also be beneficial in pathogenesis studies to study the entire spectrum of Lassa fever severity.
Collapse
Affiliation(s)
- Mathieu Mateo
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon France
| | - Jimmy Hortion
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon France
| | - Emeline Perthame
- Bioinformatics and Biostatistics Hub, Institut Pasteur, Université de Paris, Paris, France
| | - Caroline Picard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon France
| | - Stéphanie Reynard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon France
| | - Alexandra Journeaux
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon France
| | - Clara Germain
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon France
| | - Xavier Carnec
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon France
| | - Nicolas Baillet
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon France
| | - Virginie Borges-Cardoso
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon France
| | - Natalia Pietrosemoli
- Bioinformatics and Biostatistics Hub, Institut Pasteur, Université de Paris, Paris, France
| | - Audrey Vallve
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, 69007 Lyon, France
| | - Stéphane Barron
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, 69007 Lyon, France
| | - Ophélie Jourjon
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, 69007 Lyon, France
| | - Orianne Lacroix
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, 69007 Lyon, France
| | - Aurélie Duthey
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, 69007 Lyon, France
| | - Manon Dirheimer
- INSERM, Délégation Régionale Auvergne Rhône-Alpes, Bron, France
| | | | | | - Gregory Jouvion
- Ecole Nationale Vétérinaire d'Alfort, Unité d'Histologie et d'Anatomie Pathologique, Maisons-Alfort, France.,Dynamic Research Group, Ecole Nationale Vétérinaired'Alfort, USC ANSES, Université Paris Est Créteil, Maisons-Alfort, France
| | | | - Hervé Raoul
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, 69007 Lyon, France
| | - Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon France
| |
Collapse
|
10
|
Li T, Cai H, Zhao Y, Li Y, Lai Y, Yao H, Liu LD, Sun Z, van Vlissingen MF, Kuiken T, GeurtsvanKessel CH, Zhang N, Zhou B, Lu L, Gong Y, Qin W, Mondal M, Duan B, Xu S, Richard AS, Raoul H, Chen J, Xu C, Wu L, Zhou H, Huang Z, Zhang X, Li J, Wang Y, Bi Y, Rockx B, Chen J, Meng F, Lavillette D, Li D. Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody. EMBO Mol Med 2021; 13:e14544. [PMID: 34672091 PMCID: PMC8646660 DOI: 10.15252/emmm.202114544] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 10/14/2021] [Accepted: 10/18/2021] [Indexed: 12/14/2022] Open
Abstract
An essential step for SARS-CoV-2 infection is the attachment to the host cell receptor by its Spike receptor-binding domain (RBD). Most of the existing RBD-targeting neutralizing antibodies block the receptor-binding motif (RBM), a mutable region with the potential to generate neutralization escape mutants. Here, we isolated and structurally characterized a non-RBM-targeting monoclonal antibody (FD20) from convalescent patients. FD20 engages the RBD at an epitope distal to the RBM with a KD of 5.6 nM, neutralizes SARS-CoV-2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross-reactivity against SARS-CoV, and reduces viral replication in hamsters. The epitope coincides with a predicted "ideal" vulnerability site with high functional and structural constraints. Mutation of the residues of the conserved epitope variably affects FD20-binding but confers little or no resistance to neutralization. Finally, in vitro mode-of-action characterization and negative-stain electron microscopy suggest a neutralization mechanism by which FD20 destructs the Spike. Our results reveal a conserved vulnerability site in the SARS-CoV-2 Spike for the development of potential antiviral drugs.
Collapse
|
11
|
Diallo MSK, Ayouba A, Keita AK, Thaurignac G, Sow MS, Kpamou C, Barry TA, Msellati P, Etard JF, Peeters M, Ecochard R, Delaporte E, Toure A, Ayouba A, Baize S, Bangoura K, Barry A, Barry M, Cissé M, Cissé M, Delaporte E, Delfraissy JF, Delmas C, Desclaux A, Diallo SB, Diallo MS, Diallo MS, Étard JF, Etienne C, Faye O, Fofana I, Granouillac B, Izard S, Kassé D, Keita AK, Keita S, Koivogui L, Kpamou C, Lacarabaratz C, Leroy S, Marchal CL, Levy Y, Magassouba N, March L, Mendiboure V, Msellati P, Niane H, Peeters M, Pers YM, Raoul H, Sacko SL, Savané I, Sow MS, Taverne B, Touré A, Traoré FA, Traoré F, Youla Y, Yazdanpanah Y. Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study. The Lancet Microbe 2021; 2:e676-e684. [DOI: 10.1016/s2666-5247(21)00170-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2021] [Revised: 06/16/2021] [Accepted: 06/16/2021] [Indexed: 12/19/2022] Open
|
12
|
Li T, Cai H, Yao H, Zhou B, Zhang N, van Vlissingen MF, Kuiken T, Han W, GeurtsvanKessel CH, Gong Y, Zhao Y, Shen Q, Qin W, Tian XX, Peng C, Lai Y, Wang Y, Hutter CAJ, Kuo SM, Bao J, Liu C, Wang Y, Richard AS, Raoul H, Lan J, Seeger MA, Cong Y, Rockx B, Wong G, Bi Y, Lavillette D, Li D. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. Nat Commun 2021; 12:4635. [PMID: 34330908 PMCID: PMC8324831 DOI: 10.1038/s41467-021-24905-z] [Citation(s) in RCA: 53] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Accepted: 07/15/2021] [Indexed: 01/15/2023] Open
Abstract
SARS-CoV-2, the causative agent of COVID-191, features a receptor-binding domain (RBD) for binding to the host cell ACE2 protein1-6. Neutralizing antibodies that block RBD-ACE2 interaction are candidates for the development of targeted therapeutics7-17. Llama-derived single-domain antibodies (nanobodies, ~15 kDa) offer advantages in bioavailability, amenability, and production and storage owing to their small sizes and high stability. Here, we report the rapid selection of 99 synthetic nanobodies (sybodies) against RBD by in vitro selection using three libraries. The best sybody, MR3 binds to RBD with high affinity (KD = 1.0 nM) and displays high neutralization activity against SARS-CoV-2 pseudoviruses (IC50 = 0.42 μg mL-1). Structural, biochemical, and biological characterization suggests a common neutralizing mechanism, in which the RBD-ACE2 interaction is competitively inhibited by sybodies. Various forms of sybodies with improved potency have been generated by structure-based design, biparatopic construction, and divalent engineering. Two divalent forms of MR3 protect hamsters from clinical signs after live virus challenge and a single dose of the Fc-fusion construct of MR3 reduces viral RNA load by 6 Log10. Our results pave the way for the development of therapeutic nanobodies against COVID-19 and present a strategy for rapid development of targeted medical interventions during an outbreak.
Collapse
Affiliation(s)
- Tingting Li
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
| | - Hongmin Cai
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
| | - Hebang Yao
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
| | - Bingjie Zhou
- University of CAS, Beijing, China
- CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China
| | - Ning Zhang
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), CAS, Beijing, China
| | - Martje Fentener van Vlissingen
- Erasmus Laboratory Animal Science Center, Erasmus University Medical Center, Rotterdam, Netherlands
- European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France
| | - Thijs Kuiken
- European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France
- Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Wenyu Han
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
- University of CAS, Beijing, China
| | - Corine H GeurtsvanKessel
- European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France
- Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Yuhuan Gong
- University of CAS, Beijing, China
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), CAS, Beijing, China
| | - Yapei Zhao
- University of CAS, Beijing, China
- CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China
| | - Quan Shen
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), CAS, Beijing, China
| | - Wenming Qin
- National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute (Zhangjiang Laboratory), CAS, Shanghai, China
| | - Xiao-Xu Tian
- National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute (Zhangjiang Laboratory), CAS, Shanghai, China
| | - Chao Peng
- National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute (Zhangjiang Laboratory), CAS, Shanghai, China
| | - Yanling Lai
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
- University of CAS, Beijing, China
| | - Yanxing Wang
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
| | - Cedric A J Hutter
- Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
| | - Shu-Ming Kuo
- CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China
| | - Juan Bao
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
| | - Caixuan Liu
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
- University of CAS, Beijing, China
| | - Yifan Wang
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
- University of CAS, Beijing, China
| | - Audrey S Richard
- European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France
| | - Hervé Raoul
- European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France
| | - Jiaming Lan
- CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China
| | - Markus A Seeger
- Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
| | - Yao Cong
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China
| | - Barry Rockx
- European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Paris, France
- Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Gary Wong
- CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China.
- Département de microbiologie-infectiologie et d'immunologie, Université Laval, Québec, QC, Canada.
| | - Yuhai Bi
- University of CAS, Beijing, China.
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early-warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), CAS, Beijing, China.
| | - Dimitri Lavillette
- CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS, Shanghai, China.
- Pasteurien College, Soochow University, Jiangsu, China.
| | - Dianfan Li
- State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (CAS), Shanghai, China.
| |
Collapse
|
13
|
Mateo M, Reynard S, Journeaux A, Germain C, Hortion J, Carnec X, Picard C, Baillet N, Borges-Cardoso V, Merabet O, Vallve A, Barron S, Jourjon O, Lacroix O, Duthey A, Dirheimer M, Jouvion G, Moreau PH, Fellmann L, Carbonnelle C, Raoul H, Tangy F, Baize S. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci Transl Med 2021; 13:13/597/eabf6348. [PMID: 34108251 DOI: 10.1126/scitranslmed.abf6348] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Revised: 02/12/2021] [Accepted: 04/15/2021] [Indexed: 12/12/2022]
Abstract
A safe and protective Lassa virus vaccine is crucially needed in Western Africa to stem the recurrent outbreaks of Lassa virus infections in Nigeria and the emergence of Lassa virus in previously unaffected countries, such as Benin and Togo. Major challenges in developing a Lassa virus vaccine include the high diversity of circulating strains and their reemergence from 1 year to another. To address each of these challenges, we immunized cynomolgus monkeys with a measles virus vector expressing the Lassa virus glycoprotein and nucleoprotein of the prototypic Lassa virus strain Josiah (MeV-NP). To evaluate vaccine efficacy against heterologous strains of Lassa virus, we challenged the monkeys a month later with heterologous strains from lineage II or lineage VII, finding that the vaccine was protective against these strains. A second cohort of monkeys was challenged 1 year later with the homologous Josiah strain, finding that a single dose of MeV-NP was sufficient to protect all vaccinated monkeys. These studies demonstrate that MeV-NP can generate both long-lasting immune responses and responses that are able to protect against diverse strains of Lassa virus.
Collapse
Affiliation(s)
- Mathieu Mateo
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007 Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007 Lyon, France
| | - Stéphanie Reynard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007 Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007 Lyon, France
| | - Alexandra Journeaux
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007 Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007 Lyon, France
| | - Clara Germain
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007 Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007 Lyon, France
| | - Jimmy Hortion
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007 Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007 Lyon, France
| | - Xavier Carnec
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007 Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007 Lyon, France
| | - Caroline Picard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007 Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007 Lyon, France
| | - Nicolas Baillet
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007 Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007 Lyon, France
| | - Virginie Borges-Cardoso
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007 Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007 Lyon, France
| | - Othmann Merabet
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007 Lyon, France.,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007 Lyon, France
| | - Audrey Vallve
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, 69007 Lyon, France
| | - Stéphane Barron
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, 69007 Lyon, France
| | - Ophélie Jourjon
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, 69007 Lyon, France
| | - Orianne Lacroix
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, 69007 Lyon, France
| | - Aurélie Duthey
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, 69007 Lyon, France
| | - Manon Dirheimer
- INSERM, Délégation Régionale Auvergne Rhône-Alpes, 69500 Bron, France
| | - Gregory Jouvion
- Ecole Nationale Vétérinaire d'Alfort, Unité d'Histologie et d'Anatomie Pathologique, 94700 Maisons-Alfort, France.,Dynamic Research Group, Université Paris Est Créteil, Ecole Nationale Vétérinaire d'Alfort, USC ANSES, 94700 Maisons-Alfort, France
| | | | - Lyne Fellmann
- SILABE, Université de Strasbourg, Fort Foch, 67207 Niederhausbergen, France
| | | | - Hervé Raoul
- Laboratoire P4 INSERM-Jean Mérieux, INSERM US003, 69007 Lyon, France
| | - Frédéric Tangy
- Viral Genomics and Vaccination, Institut Pasteur, CNRS UMR-3569, 75015 Paris, France
| | - Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, 69007 Lyon, France. .,Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, INSERM U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, 69007 Lyon, France
| |
Collapse
|
14
|
Reynard S, Gloaguen E, Baillet N, Madelain V, Guedj J, Raoul H, de Lamballerie X, Mullaert J, Baize S. Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates. PLoS Negl Trop Dis 2021; 15:e0009300. [PMID: 33780452 PMCID: PMC8031739 DOI: 10.1371/journal.pntd.0009300] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 04/08/2021] [Accepted: 03/09/2021] [Indexed: 12/02/2022] Open
Abstract
Ebola virus has been responsible for two major epidemics over the last several years and there has been a strong effort to find potential treatments that can improve the disease outcome. Antiviral favipiravir was thus tested on non-human primates infected with Ebola virus. Half of the treated animals survived the Ebola virus challenge, whereas the infection was fully lethal for the untreated ones. Moreover, the treated animals that did not survive died later than the controls. We evaluated the hematological, virological, biochemical, and immunological parameters of the animals and performed proteomic analysis at various timepoints of the disease. The viral load strongly correlated with dysregulation of the biological functions involved in pathogenesis, notably the inflammatory response, hemostatic functions, and response to stress. Thus, the management of viral replication in Ebola virus disease is of crucial importance in preventing the immunopathogenic disorders and septic-like shock syndrome generally observed in Ebola virus-infected patients. Ebola virus was responsible for several epidemics in the recent years and is now considered as a major public health concern in Central and West African countries. We and others demonstrated that pathogenic events observed during Ebola virus disease are linked to a deleterious immune response. However, the mechanisms implicated are not fully understood. Here, we studied immune responses depending on the viral loads observed in infected cynomolgus monkeys. An antiviral treatment allowed the reduction of viral load in some animals and we observed that these animals did not experience deleterious immune response and the loss of hemostasis. The release of pathogen-associated molecular patterns may thus be limited by the inhibition of viral replication, avoiding the overstimulation of the immune system and consequently the pathogenic events observed in Ebola virus disease.
Collapse
Affiliation(s)
- Stéphanie Reynard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France
| | | | - Nicolas Baillet
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France
| | | | | | - Hervé Raoul
- Laboratoire P4 Jean Mérieux–INSERM, INSERM US003, Lyon, France
| | - Xavier de Lamballerie
- Unité des Virus Émergents (UVE Aix-Marseille Université-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
| | | | - Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France
- * E-mail:
| |
Collapse
|
15
|
Madelain V, Mentré F, Baize S, Anglaret X, Laouénan C, Oestereich L, Nguyen THT, Malvy D, Piorkowski G, Graw F, Günther S, Raoul H, de Lamballerie X, Guedj J. Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. CPT Pharmacometrics Syst Pharmacol 2020; 9:258-271. [PMID: 32198838 PMCID: PMC7239338 DOI: 10.1002/psp4.12510] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Accepted: 12/30/2019] [Indexed: 12/14/2022]
Abstract
In 2014, our research network was involved in the evaluation of favipiravir, an anti-influenza polymerase inhibitor, against Ebola virus. In this review, we discuss how mathematical modeling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a nonhuman primate (NHP) model. The data collected in NHPs were finally used to develop a model of Ebola pathogenesis integrating the interactions among the virus, the innate and adaptive immune response, and the action of favipiravir. We conclude the review of this work by discussing how these results are of relevance for future human studies in the context of Ebola virus, but also for other emerging viral diseases for which no therapeutics are available.
Collapse
Affiliation(s)
| | | | - Sylvain Baize
- UBIVE, Institut Pasteur, Centre International de Recherche en Infectiologie, Lyon, France
| | - Xavier Anglaret
- INSERM, UMR 1219, Université de Bordeaux, Bordeaux, France.,Programme PACCI/site ANRS de Côte d'Ivoire, Abidjan, Côte d'Ivoire
| | | | - Lisa Oestereich
- Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany.,German Center for Infection Research (DZIF), Partner Site Hamburg, Germany
| | | | - Denis Malvy
- INSERM, UMR 1219, Université de Bordeaux, Bordeaux, France.,Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Géraldine Piorkowski
- UMR "Emergence des Pathologies Virales" (EPV: Aix-Marseille University - IRD 190 - Inserm 1207 - EHESP) - Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France
| | - Frederik Graw
- Center for Modeling and Simulation in the Biosciences (BIOMS), BioQuant-Center, Heidelberg University, Heidelberg, Germany
| | - Stephan Günther
- Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany.,German Center for Infection Research (DZIF), Partner Site Hamburg, Germany
| | - Hervé Raoul
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, Lyon, France
| | - Xavier de Lamballerie
- UMR "Emergence des Pathologies Virales" (EPV: Aix-Marseille University - IRD 190 - Inserm 1207 - EHESP) - Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France
| | | |
Collapse
|
16
|
Madelain V, Duthey A, Mentré F, Jacquot F, Solas C, Lacarelle B, Vallvé A, Barron S, Barrot L, Mundweiler S, Thomas D, Carbonnelle C, Raoul H, de Lamballerie X, Guedj J. Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates. Antiviral Res 2020; 177:104758. [PMID: 32135218 DOI: 10.1016/j.antiviral.2020.104758] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2019] [Revised: 02/24/2020] [Accepted: 02/26/2020] [Indexed: 01/26/2023]
Abstract
BACKGROUND In spite of recurrent and dramatic outbreaks, there are no therapeutics approved against Ebola virus disease. Favipiravir, a RNA polymerase inhibitor active against several RNA viruses, recently demonstrated significant but not complete protection in a non-human primate model of Ebola virus disease. In this study, we assessed the benefit of the combination of favipiravir and ribavirin, another broad spectrum antiviral agent, in the same model. METHODS 15 female cynomolgus macaques were challenged intramuscularly with 1,000 FFU of Ebola virus Gabon 2001 strain and followed for 21 days. All animals received favipiravir 180 mg/kg twice a day (BID), either as monotherapy (n = 5) or in combination with ribavirin (n = 10). Ribavirin was given either at the dose 10 mg/kg BID (n = 5) or 5 mg/kg BID (n = 5). Favipiravir and ribavirin were initiated two and one days before viral challenge respectively and treatment were continued for 14 days. Treatment effects on viral and hematological markers were assessed using a mathematical model. Survival rate of 0% and 20% were obtained in macaques receiving favipiravir plus ribavirin 10 and 5 mg/kg BID, respectively, compared to 40% in the favipiravir monotherapy group (P = 0.061 when comparing monotherapy and bitherapy, log rank). Viral dynamic modeling analysis did not identify an association between plasma concentrations of ribavirin and viral load levels. Using a model of erythropoiesis, plasma concentrations of ribavirin were strongly associated with a hemoglobin drop (p = 0.0015). CONCLUSION Ribavirin plus favipiravir did not extend survival rates and did not lower viral replication rate compared to favipiravir monotherapy in this animal model. Patients receiving this combination in other indications, such as Lassa fever, should be closely monitored to prevent potential toxicity associated with anemia.
Collapse
Affiliation(s)
| | - Aurélie Duthey
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, 69365, Lyon, France
| | - France Mentré
- Université de Paris, IAME, INSERM, F-75018, Paris, France
| | - Frédéric Jacquot
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, 69365, Lyon, France
| | - Caroline Solas
- Aix-Marseille Univ, APHM, UMR "Emergence des Pathologies Virales" IRD190-Inserm1207-EHESP, Laboratoire Pharmacocinétique-Toxicologie, Hôpital La Timone, 13005, Marseille, France
| | - Bruno Lacarelle
- Aix-Marseille Univ, APHM, UMR "Emergence des Pathologies Virales" IRD190-Inserm1207-EHESP, Laboratoire Pharmacocinétique-Toxicologie, Hôpital La Timone, 13005, Marseille, France
| | - Audrey Vallvé
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, 69365, Lyon, France
| | - Stéphane Barron
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, 69365, Lyon, France
| | - Laura Barrot
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, 69365, Lyon, France
| | | | - Damien Thomas
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, 69365, Lyon, France
| | | | - Hervé Raoul
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, 69365, Lyon, France
| | - Xavier de Lamballerie
- UMR "Emergence des Pathologies Virales" (EPV: Aix-Marseille University - IRD 190 - Inserm 1207 - EHESP), Institut Hospitalo-Universitaire Méditerranée Infection, F-13385, Marseille, France
| | - Jérémie Guedj
- Université de Paris, IAME, INSERM, F-75018, Paris, France.
| |
Collapse
|
17
|
Racine T, Denizot M, Pannetier D, Nguyen L, Pasquier A, Raoul H, Saluzzo JF, Kobinger G, Veas F, Herbreteau CH. In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab')2. J Infect Dis 2020; 220:41-45. [PMID: 30852585 DOI: 10.1093/infdis/jiz068] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2018] [Accepted: 02/11/2019] [Indexed: 12/21/2022] Open
Abstract
There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab')2, against EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG polyclonal antibodies with high neutralization activity. Highly purified equine anti-Ebola F(ab')2 showed strong cross-neutralization of 2 Zaire EBOV strains (Gabon 2001 and Makona) and in vivo 3 or 5 daily F(ab')2 intraperitoneal injections provided 100% protection to BALB/c mice against lethal EBOV challenge. Rapid preparation of purified equine anti-Ebola F(ab')2 offers a potentially efficient therapeutic approach against EBOV disease in humans.
Collapse
Affiliation(s)
- Trina Racine
- Special Pathogens Program, National Microbiology Laboratory, Winnipeg, Canada.,Department of Medical Microbiology, Winnipeg, Canada.,Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire de Québec, Université Laval, Canada
| | | | | | | | | | - Hervé Raoul
- INSERM, Jean Mérieux BSL-4 Laboratory, Lyon, France
| | | | - Gary Kobinger
- Department of Medical Microbiology, Winnipeg, Canada.,Department of Immunology, University of Manitoba, Winnipeg, Canada.,Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire de Québec, Université Laval, Canada.,Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia
| | - Francisco Veas
- Institut de Recherche pour le Développement, UMR-Ministère de la Défense, Faculté de Pharmacie, Université de Montpellier, France
| | | |
Collapse
|
18
|
Thirion L, Charrel RN, Boehmann Y, Corcostegui I, Raoul H, de Lamballerie X. Development and Evaluation of a Duo Zaire ebolavirus Real-Time RT-PCR Assay Targeting Two Regions within the Genome. Microorganisms 2019; 7:microorganisms7120652. [PMID: 31817185 PMCID: PMC6956279 DOI: 10.3390/microorganisms7120652] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Revised: 11/27/2019] [Accepted: 11/29/2019] [Indexed: 12/23/2022] Open
Abstract
Preparedness and response actions to mitigate Ebola virus disease (EVD) outbreaks rely on rapid diagnosis to be implemented locally to sort suspect patients attending health centers. Our aim was (i) to develop and evaluate an RT-qPCR assay combining primers and probes derived from two reference assays targeting different genomic regions; (ii) to study whether sensitivity and specificity of this dual-target assay were at least equal or better to the parental assays; (iii) to implement this dual-target assay onto the Cepheid GeneXpert open cartridge as a proof of principle for technological transfer aiming at bedsite testing locally. To do so, three home-made published RT-qPCR assays were selected to be compared with the RealStar® Filovirus Screen RT-PCR kit 1.0 (Altona Diagnostics, Hamburg, Germany), a technique that was largely deployed during the 2014–2015 West African EVD outbreak. Primers and probes sequences of the custom-made assays were analyzed in silico against a multiple sequence alignment, including >250 complete sequences corresponding to strains that have caused EVD epidemics in the past. Genomic RNA purified from the Mekambo strain of Zaire ebolavirus (EBOV) was used to study the sensitivity of the five methods. Based on these results, two in-house methods were selected and adapted to design the dual-target assay, which performances were compared to those of the parental assays using a synthetic RNA control. The dual-target assay showed better sensitivity and limit of detection (LoD95 at 0.4 copies/µL) than the parental methods (1.7 and 2.2 copies/µL). Ultimately, the dual-target assay was transferred onto the GeneXpert Flex-03 open cartridge, demonstrating a LoD95 at 0.75 copies/µL. Together these results indicate that EBOV dual-target assay has the potential to be used during EVD outbreak in the laboratory having performed molecular testing during the recent outbreaks.
Collapse
Affiliation(s)
- Laurence Thirion
- Unité des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM U1207, IHU Méditerranée Infection), Aix Marseille Universite, Marseille 13000, France; (L.T.); (Y.B.); (I.C.); (X.d.L.)
| | - Remi N. Charrel
- Unité des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM U1207, IHU Méditerranée Infection), Aix Marseille Universite, Marseille 13000, France; (L.T.); (Y.B.); (I.C.); (X.d.L.)
- Correspondence:
| | - Yannik Boehmann
- Unité des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM U1207, IHU Méditerranée Infection), Aix Marseille Universite, Marseille 13000, France; (L.T.); (Y.B.); (I.C.); (X.d.L.)
| | - Iban Corcostegui
- Unité des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM U1207, IHU Méditerranée Infection), Aix Marseille Universite, Marseille 13000, France; (L.T.); (Y.B.); (I.C.); (X.d.L.)
| | - Hervé Raoul
- Laboratory P4-Jean Mérieux, INSERM, Lyon 69007, France;
| | - Xavier de Lamballerie
- Unité des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM U1207, IHU Méditerranée Infection), Aix Marseille Universite, Marseille 13000, France; (L.T.); (Y.B.); (I.C.); (X.d.L.)
| |
Collapse
|
19
|
Mateo M, Reynard S, Carnec X, Journeaux A, Baillet N, Schaeffer J, Picard C, Legras-Lachuer C, Allan R, Perthame E, Hillion KH, Pietrosemoli N, Dillies MA, Barrot L, Vallve A, Barron S, Fellmann L, Gaillard JC, Armengaud J, Carbonnelle C, Raoul H, Tangy F, Baize S. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Sci Transl Med 2019; 11:11/512/eaaw3163. [DOI: 10.1126/scitranslmed.aaw3163] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2018] [Revised: 04/16/2019] [Accepted: 08/02/2019] [Indexed: 01/01/2023]
Abstract
Lassa fever is a major threat in Western Africa. The large number of people living at risk for this disease calls for the development of a vaccine against Lassa virus (LASV). We generated live-attenuated LASV vaccines based on measles virus and Mopeia virus platforms and expressing different LASV antigens, with the aim to develop a vaccine able to protect after a single shot. We compared the efficacy of these vaccines against LASV in cynomolgus monkeys. The vaccines were well tolerated and protected the animals from LASV infection and disease after a single immunization but with varying efficacy. Analysis of the immune responses showed that complete protection was associated with robust secondary T cell and antibody responses against LASV. Transcriptomic and proteomic analyses showed an early activation of innate immunity and T cell priming after immunization with the most effective vaccines, with changes detectable as early as 2 days after immunization. The most efficacious vaccine candidate, a measles vector simultaneously expressing LASV glycoprotein and nucleoprotein, has been selected for further clinical evaluation.
Collapse
|
20
|
Mateo M, Reynard S, Baillet N, Carnec X, Fizet A, Jourdain M, Picard C, Schaeffer J, Barrot L, Barron S, Vallve A, Raoul H, Carbonnelle C, Tangy F, Baize S. One-shot immunization using a Measles/Lassa vaccine fully protects cynomolgus monkeys against Lassa fever. Int J Infect Dis 2019. [DOI: 10.1016/j.ijid.2018.11.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
21
|
Reynard S, Journeaux A, Gloaguen E, Schaeffer J, Varet H, Pietrosemoli N, Mateo M, Baillet N, Laouenan C, Raoul H, Mullaert J, Baize S. Immune parameters and outcomes during Ebola virus disease. JCI Insight 2019; 4:125106. [PMID: 30626757 DOI: 10.1172/jci.insight.125106] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Accepted: 11/29/2018] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND The West African Ebola virus epidemic from 2014-2016 highlighted the lack of knowledge about the pathogenicity of the virus and the factors responsible for outcome. A performant and rapid diagnosis is of crucial importance, as is overcoming the difficulty of providing high-quality patient management during such an extensive outbreak. Here, we propose to study the role of the immune mediators during Ebola virus disease and to define some molecules of importance in the outcome. METHODS Plasma from Guinean patients sampled during the outbreak were analyzed using RT-qPCR, magnetic bead assay, ELISA, and high-quality statistical analyses. We also performed a transcriptomic analysis in leukocytes samples. Therefore, we deeply characterized the immune responses involved in Ebola virus disease. RESULTS We evaluated the immune patterns depending on the outcome of the disease. Survivors presented an efficient and well-balanced immune response, whereas fatalities were characterized by an intense inflammatory response, overexpression of multiple cytokines, and a "chemokine storm." The plasma concentration of most of the parameters tested increased until death. Statistical analyses also allowed us to define a panel of markers highly predictive of outcome. CONCLUSION The immune response observed in fatalities was highly similar to that characterizing septic shock syndrome. Our results suggest that immune responses can play a major pathogenic role during severe Ebola virus infection and argue in favor of therapeutic approaches that act on both viral replication and the induction of shock syndrome. FUNDING French Ministry of Foreign Affairs, the Agence Française de Développement, and the Institut Pasteur.
Collapse
Affiliation(s)
- Stéphanie Reynard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie, Université Lyon I, INSERM, CNRS, ENS Lyon, Lyon, France
| | - Alexandra Journeaux
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie, Université Lyon I, INSERM, CNRS, ENS Lyon, Lyon, France
| | - Emilie Gloaguen
- Infection Antimicrobials Modelling Evolution, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Justine Schaeffer
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie, Université Lyon I, INSERM, CNRS, ENS Lyon, Lyon, France
| | - Hugo Varet
- Institut Pasteur, Hub Bioinformatique et Biostatistique, Centre de Bioinformatique, Biostatistique et Biologie Intégrative, C3BI, USR 3756 IP CNRS, Paris, France
| | - Natalia Pietrosemoli
- Institut Pasteur, Hub Bioinformatique et Biostatistique, Centre de Bioinformatique, Biostatistique et Biologie Intégrative, C3BI, USR 3756 IP CNRS, Paris, France
| | - Mathieu Mateo
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie, Université Lyon I, INSERM, CNRS, ENS Lyon, Lyon, France
| | - Nicolas Baillet
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie, Université Lyon I, INSERM, CNRS, ENS Lyon, Lyon, France
| | - Cédric Laouenan
- Infection Antimicrobials Modelling Evolution, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Assistance Publique - Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Paris, France
| | - Hervé Raoul
- Laboratoire P4 Jean Mérieux-INSERM, INSERM, Lyon, France
| | - Jimmy Mullaert
- Infection Antimicrobials Modelling Evolution, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie, Université Lyon I, INSERM, CNRS, ENS Lyon, Lyon, France
| |
Collapse
|
22
|
Romette JL, Prat CM, Gould EA, de Lamballerie X, Charrel R, Coutard B, Fooks AR, Bardsley M, Carroll M, Drosten C, Drexler JF, Günther S, Klempa B, Pinschewer D, Klimkait T, Avsic-Zupanc T, Capobianchi MR, Dicaro A, Ippolito G, Nitsche A, Koopmans M, Reusken C, Gorbalenya A, Raoul H, Bourhy H, Mettenleiter T, Reiche S, Batten C, Sabeta C, Paweska JT, Eropkin M, Zverev V, Hu Z, Mac Cullough S, Mirazimi A, Pradel F, Lieutaud P. The European Virus Archive goes global: A growing resource for research. Antiviral Res 2018; 158:127-134. [PMID: 30059721 PMCID: PMC7127435 DOI: 10.1016/j.antiviral.2018.07.017] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Revised: 07/21/2018] [Accepted: 07/23/2018] [Indexed: 11/28/2022]
Abstract
The European Virus Archive (EVA) was created in 2008 with funding from the FP7-EU Infrastructure Programme, in response to the need for a coordinated and readily accessible collection of viruses that could be made available to academia, public health organisations and industry. Within three years, it developed from a consortium of nine European laboratories to encompass associated partners in Africa, Russia, China, Turkey, Germany and Italy. In 2014, the H2020 Research and Innovation Framework Programme (INFRAS projects) provided support for the transformation of the EVA from a European to a global organization (EVAg). The EVAg now operates as a non-profit consortium, with 26 partners and 20 associated partners from 21 EU and non-EU countries. In this paper, we outline the structure, management and goals of the EVAg, to bring to the attention of researchers the wealth of products it can provide and to illustrate how end-users can gain access to these resources. Organisations or individuals who would like to be considered as contributors are invited to contact the EVAg coordinator, Jean-Louis Romette, at jean-louis.romette@univmed.fr.
Collapse
Affiliation(s)
- J L Romette
- Unite des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France.
| | - C M Prat
- Unite des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France
| | - E A Gould
- Unite des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France
| | - X de Lamballerie
- Unite des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France
| | - R Charrel
- Unite des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France
| | - B Coutard
- Architectures et Fonctions, des Macromolécules, Biologiques, Marseille, France
| | - A R Fooks
- Animal and Plant Health Agency, Weybridge, United Kingdom
| | - M Bardsley
- Animal and Plant Health Agency, Weybridge, United Kingdom
| | - M Carroll
- Department of Health-Special Pathogens Laboratory, Porton Down, United Kingdom
| | - C Drosten
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, 10117 Berlin, Germany
| | - J F Drexler
- Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, 10117 Berlin, Germany
| | - S Günther
- Department of Virology, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - B Klempa
- Biomedical Research Center, Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovakia
| | - D Pinschewer
- Department of Pathology and Immunology, University of Bales, Switzerland
| | - T Klimkait
- Department of Pathology and Immunology, University of Bales, Switzerland
| | - T Avsic-Zupanc
- Institute of Microbiology and Immunology, Lubljana, Slovenia
| | | | - A Dicaro
- UOC, Istituto Nazionale Malattie Infettive Roma, Italy
| | - G Ippolito
- UOC, Istituto Nazionale Malattie Infettive Roma, Italy
| | - A Nitsche
- Robert Koch Institut, Berlin, Germany
| | - M Koopmans
- ERASMUS Medical Center, Rotterdam, The Netherlands
| | - C Reusken
- ERASMUS Medical Center, Rotterdam, The Netherlands
| | - A Gorbalenya
- Leiden University Medical Center, Leiden, The Netherlands
| | - H Raoul
- Laboratoire Merieux, INSERM, Lyon, France
| | | | - T Mettenleiter
- Friedrich Loeffler Institut, Greifswald-Insel Riems, Germany
| | - S Reiche
- Friedrich Loeffler Institut, Greifswald-Insel Riems, Germany
| | - C Batten
- The Pirbright Institute, Pirbright, United Kingdom
| | - C Sabeta
- Onderstepoort Veterinary Institute, Praetoria, South Africa
| | - J T Paweska
- National Institute for Communicable Diseases, Johannesburg, South Africa
| | - M Eropkin
- Research Institute of Influenza, St. Petersburg, Russia
| | - V Zverev
- Mechnikov Scientific Research Institute for Vaccines and Sera, Moscow, Russia
| | - Z Hu
- Wuhan Institute of Virology, Wuhan, China
| | - S Mac Cullough
- Australian Animal Health Laboratory, Geelong, Australia Disease, Johannesburg, South Africa
| | | | - F Pradel
- Fondation Mérieux, réseau GABRIEL, Lyon, France
| | - P Lieutaud
- Unite des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection), Marseille, France
| |
Collapse
|
23
|
Madelain V, Baize S, Jacquot F, Reynard S, Fizet A, Barron S, Solas C, Lacarelle B, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X, Guedj J. Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Nat Commun 2018; 9:4013. [PMID: 30275474 PMCID: PMC6167368 DOI: 10.1038/s41467-018-06215-z] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Accepted: 08/23/2018] [Indexed: 01/12/2023] Open
Abstract
Despite several clinical trials implemented, no antiviral drug could demonstrate efficacy against Ebola virus. In non-human primates, early initiation of polymerase inhibitors favipiravir and remdesivir improves survival, but whether they could be effective in patients is unknown. Here we analyze the impact of antiviral therapy by using a mathematical model that integrates virological and immunological data of 44 cynomolgus macaques, left untreated or treated with favipiravir. We estimate that favipiravir has a ~50% efficacy in blocking viral production, which results in reducing virus growth and cytokine storm while IFNα reduces cell susceptibility to infection. Simulating the effect of delayed initiations of treatment, our model predicts survival rates of 60% for favipiravir and 100% for remdesivir when treatment is initiated within 3 and 4 days post infection, respectively. These results improve the understanding of Ebola immuno-pathogenesis and can help optimize antiviral evaluation in future outbreaks.
Collapse
Affiliation(s)
- Vincent Madelain
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité Paris, 75018, Paris, France.
| | - Sylvain Baize
- UBIVE, Institut Pasteur, Centre International de Recherche en Infectiologie, 69007, Lyon, France
| | - Frédéric Jacquot
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, 69365, Lyon, France
| | - Stéphanie Reynard
- UBIVE, Institut Pasteur, Centre International de Recherche en Infectiologie, 69007, Lyon, France
| | - Alexandra Fizet
- UBIVE, Institut Pasteur, Centre International de Recherche en Infectiologie, 69007, Lyon, France
| | - Stephane Barron
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, 69365, Lyon, France
| | - Caroline Solas
- Aix-Marseille Univ U105, APHM, SMARTc CRCM Inserm UMR1068 CNRS UMR7258, Hôpital La Timone, Laboratoire de Pharmacocinétique et Toxicologie, 13005, Marseille, France
| | - Bruno Lacarelle
- Aix-Marseille Univ U105, APHM, SMARTc CRCM Inserm UMR1068 CNRS UMR7258, Hôpital La Timone, Laboratoire de Pharmacocinétique et Toxicologie, 13005, Marseille, France
| | | | - France Mentré
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité Paris, 75018, Paris, France
| | - Hervé Raoul
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, 69365, Lyon, France
| | - Xavier de Lamballerie
- UMR "Emergence des Pathologies Virales" (EPV: Aix-Marseille university - IRD 190 - Inserm 1207 - EHESP) - Institut Hospitalo-Universitaire Méditerranée Infection, 13385, Marseille, France
| | - Jérémie Guedj
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité Paris, 75018, Paris, France
| |
Collapse
|
24
|
Ferraris O, Casalegno JS, Frobert E, Bouscambert Duchamp M, Valette M, Jacquot F, Raoul H, Lina B, Ottmann M. The NS Segment of H1N1pdm09 Enhances H5N1 Pathogenicity in a Mouse Model of Influenza Virus Infections. Viruses 2018; 10:v10090504. [PMID: 30227598 PMCID: PMC6164720 DOI: 10.3390/v10090504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Revised: 09/13/2018] [Accepted: 09/15/2018] [Indexed: 11/17/2022] Open
Abstract
In 2009, the co-circulation of H5N1 and H1N1pdm09 raised concerns that a reassortment event may lead to highly pathogenic influenza strains. H1N1pdm09 and H5N1 are able to infect the same target cells of the lower respiratory tract. To investigate the capacity of the emergence of reassortant viruses, we characterized viruses obtained from the co-infection of cells with H5N1 (A/Turkey/13/2006) and H1N1pdm09 (A/Lyon/969/2009 H1N1). In our analysis, all the screened reassortants possessed the PB2, HA, and NP segments from H5N1 and acquired one or two of the H1N1pdm09 segments. Moreover, the in vivo infections showed that the acquisition of the NS segment from H1N1pdm09 increased the virulence of H5N1 in mice. We conclude, therefore, that reassortment can occur between these two viruses, even if this process has never been detected in nature.
Collapse
Affiliation(s)
- Olivier Ferraris
- Laboratoire de Virologie et Pathologies Humaines Virpath, CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, 69372 CEDEX 08 Lyon, France.
| | - Jean-Sébastien Casalegno
- Laboratoire de Virologie et Pathologies Humaines Virpath, CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, 69372 CEDEX 08 Lyon, France.
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord des Hospices Civils de Lyon, 69317 CEDEX 04 Lyon, France.
| | - Emilie Frobert
- Laboratoire de Virologie et Pathologies Humaines Virpath, CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, 69372 CEDEX 08 Lyon, France.
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord des Hospices Civils de Lyon, 69317 CEDEX 04 Lyon, France.
| | - Maude Bouscambert Duchamp
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord des Hospices Civils de Lyon, 69317 CEDEX 04 Lyon, France.
| | - Martine Valette
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord des Hospices Civils de Lyon, 69317 CEDEX 04 Lyon, France.
- Laboratoire de Virologie, Centre National de Référence Virus des Infections Respiratoires, Groupement Hospitalier Nord des Hospices Civils de Lyon, 69317 CEDEX 04 Lyon, France.
| | - Frédéric Jacquot
- Laboratoire P4 Jean Mérieux Inserm US003, 69365 CEDEX 07 Lyon, France.
| | - Hervé Raoul
- Laboratoire P4 Jean Mérieux Inserm US003, 69365 CEDEX 07 Lyon, France.
| | - Bruno Lina
- Laboratoire de Virologie et Pathologies Humaines Virpath, CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, 69372 CEDEX 08 Lyon, France.
- Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord des Hospices Civils de Lyon, 69317 CEDEX 04 Lyon, France.
- Laboratoire de Virologie, Centre National de Référence Virus des Infections Respiratoires, Groupement Hospitalier Nord des Hospices Civils de Lyon, 69317 CEDEX 04 Lyon, France.
| | - Michèle Ottmann
- Laboratoire de Virologie et Pathologies Humaines Virpath, CIRI, Centre International de Recherche en Infectiologie, Université de Lyon, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, 69372 CEDEX 08 Lyon, France.
| |
Collapse
|
25
|
Carnec X, Mateo M, Page A, Reynard S, Hortion J, Picard C, Yekwa E, Barrot L, Barron S, Vallve A, Raoul H, Carbonnelle C, Ferron F, Baize S. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins. J Virol 2018; 92:e02230-17. [PMID: 29593043 PMCID: PMC5974477 DOI: 10.1128/jvi.02230-17] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Accepted: 03/22/2018] [Indexed: 11/20/2022] Open
Abstract
Several Old World and New World arenaviruses are responsible for severe endemic and epidemic hemorrhagic fevers, whereas other members of the Arenaviridae family are nonpathogenic. To date, no approved vaccines, antivirals, or specific treatments are available, except for Junín virus. However, protection of nonhuman primates against Lassa fever virus (LASV) is possible through the inoculation of the closely related but nonpathogenic Mopeia virus (MOPV) before challenge with LASV. We reasoned that this virus, modified by using reverse genetics, would represent the basis for the generation of a vaccine platform against LASV and other pathogenic arenaviruses. After showing evidence of exoribonuclease (ExoN) activity in NP of MOPV, we found that this activity was essential for multiplication in antigen-presenting cells. The introduction of multiple mutations in the ExoN site of MOPV NP generated a hyperattenuated strain (MOPVExoN6b) that is (i) genetically stable over passages, (ii) has increased immunogenic properties compared to those of MOPV, and (iii) still promotes a strong type I interferon (IFN) response. MOPVExoN6b was further modified to harbor the envelope glycoproteins of heterologous pathogenic arenaviruses, such as LASV or Lujo, Machupo, Guanarito, Chapare, or Sabia virus in order to broaden specific antigenicity while preserving the hyperattenuated characteristics of the parental strain. Our MOPV-based vaccine candidate for LASV, MOPEVACLASV, was used in a one-shot immunization assay in nonhuman primates and fully protected them from a lethal challenge with LASV. Thus, our hyperattenuated strain of MOPV constitutes a promising new live-attenuated vaccine platform to immunize against several, if not all, pathogenic arenaviruses.IMPORTANCE Arenaviruses are emerging pathogens transmitted to humans by rodents and responsible for endemic and epidemic hemorrhagic fevers of global concern. Nonspecific symptoms associated with the onset of infection make these viruses difficult to distinguish from other endemic pathogens. Moreover, the unavailability of rapid diagnosis in the field delays the identification of the virus and early care for treatment and favors spreading. The vaccination of exposed populations would be of great help to decrease morbidity and human-to-human transmission. Using reverse genetics, we generated a vaccine platform for pathogenic arenaviruses based on a modified and hyperattenuated strain of the nonpathogenic Mopeia virus and showed that the Lassa virus candidate fully protected nonhuman primates from a lethal challenge. These results showed that a rationally designed recombinant MOPV-based vaccine is safe, immunogenic, and efficacious in nonhuman primates.
Collapse
Affiliation(s)
- Xavier Carnec
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie (INSERM, CNRS, ENS Lyon, Université Lyon I), Lyon, France
| | - Mathieu Mateo
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie (INSERM, CNRS, ENS Lyon, Université Lyon I), Lyon, France
| | - Audrey Page
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie (INSERM, CNRS, ENS Lyon, Université Lyon I), Lyon, France
| | - Stéphanie Reynard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie (INSERM, CNRS, ENS Lyon, Université Lyon I), Lyon, France
| | - Jimmy Hortion
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie (INSERM, CNRS, ENS Lyon, Université Lyon I), Lyon, France
| | - Caroline Picard
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie (INSERM, CNRS, ENS Lyon, Université Lyon I), Lyon, France
| | - Elsie Yekwa
- CNRS, Architecture et Fonction des Macromolécules Biologiques UMR 7257, Aix-Marseille Université, Marseille, France
| | - Laura Barrot
- Laboratoire P4 Jean Mérieux-INSERM, US003, INSERM, Lyon, France
| | - Stéphane Barron
- Laboratoire P4 Jean Mérieux-INSERM, US003, INSERM, Lyon, France
| | - Audrey Vallve
- Laboratoire P4 Jean Mérieux-INSERM, US003, INSERM, Lyon, France
| | - Hervé Raoul
- Laboratoire P4 Jean Mérieux-INSERM, US003, INSERM, Lyon, France
| | | | - François Ferron
- CNRS, Architecture et Fonction des Macromolécules Biologiques UMR 7257, Aix-Marseille Université, Marseille, France
| | - Sylvain Baize
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie (INSERM, CNRS, ENS Lyon, Université Lyon I), Lyon, France
| |
Collapse
|
26
|
Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, Gunther S, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Med 2018; 15:e1002535. [PMID: 29584730 PMCID: PMC5870946 DOI: 10.1371/journal.pmed.1002535] [Citation(s) in RCA: 85] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Accepted: 02/14/2018] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Despite repeated outbreaks, in particular the devastating 2014-2016 epidemic, there is no effective treatment validated for patients with Ebola virus disease (EVD). Among the drug candidates is the broad-spectrum polymerase inhibitor favipiravir, which showed a good tolerance profile in patients with EVD (JIKI trial) but did not demonstrate a strong antiviral efficacy. In order to gain new insights into the antiviral efficacy of favipiravir and improve preparedness and public health management of future outbreaks, we assess the efficacy achieved by ascending doses of favipiravir in Ebola-virus-infected nonhuman primates (NHPs). METHODS AND FINDINGS A total of 26 animals (Macaca fascicularis) were challenged intramuscularly at day 0 with 1,000 focus-forming units of Ebola virus Gabon 2001 strain and followed for 21 days (study termination). This included 13 animals left untreated and 13 treated with doses of 100, 150, and 180 mg/kg (N = 3, 5, and 5, respectively) favipiravir administered intravenously twice a day for 14 days, starting 2 days before infection. All animals left untreated or treated with 100 mg/kg died within 10 days post-infection, while animals receiving 150 and 180 mg/kg had extended survival (P < 0.001 and 0.001, respectively, compared to untreated animals), leading to a survival rate of 40% (2/5) and 60% (3/5), respectively, at day 21. Favipiravir inhibited viral replication (molecular and infectious viral loads) in a drug-concentration-dependent manner (P values < 0.001), and genomic deep sequencing analyses showed an increase in virus mutagenesis over time. These results allowed us to identify that plasma trough favipiravir concentrations greater than 70-80 μg/ml were associated with reduced viral loads, lower virus infectivity, and extended survival. These levels are higher than those found in the JIKI trial, where patients had median trough drug concentrations equal to 46 and 26 μg/ml at day 2 and day 4 post-treatment, respectively, and suggest that the dosing regimen in the JIKI trial was suboptimal. The environment of a biosafety level 4 laboratory introduces a number of limitations, in particular the difficulty of conducting blind studies and performing detailed pharmacological assessments. Further, the extrapolation of the results to patients with EVD is limited by the fact that the model is fully lethal and that treatment initiation in patients with EVD is most often initiated several days after infection, when symptoms and high levels of viral replication are already present. CONCLUSIONS Our results suggest that favipiravir may be an effective antiviral drug against Ebola virus that relies on RNA chain termination and possibly error catastrophe. These results, together with previous data collected on tolerance and pharmacokinetics in both NHPs and humans, support a potential role for high doses of favipiravir for future human interventions.
Collapse
Affiliation(s)
- Jérémie Guedj
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- * E-mail:
| | - Géraldine Piorkowski
- UMR Émergence des Pathologies Virales, Aix-Marseille University, IRD 190, Inserm 1207, École des Hautes Études en Santé Publique, Marseille, France
| | | | - Vincent Madelain
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Thi Huyen Tram Nguyen
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Anne Rodallec
- UMR Émergence des Pathologies Virales, Aix-Marseille University, IRD 190, Inserm 1207, École des Hautes Études en Santé Publique, Marseille, France
- SMARTc Unit, U911 Cro2, Aix-Marseille University, Marseille, France
| | - Stephan Gunther
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | | | - France Mentré
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Hervé Raoul
- Laboratoire P4 Inserm–Jean Mérieux, US003 Inserm, Lyon, France
| | - Xavier de Lamballerie
- UMR Émergence des Pathologies Virales, Aix-Marseille University, IRD 190, Inserm 1207, École des Hautes Études en Santé Publique, Marseille, France
| |
Collapse
|
27
|
Subtil F, Delaunay C, Keita AK, Sow MS, Touré A, Leroy S, Msellati P, Magassouba N, Baize S, Raoul H, Ecochard R, Barry M, Delaporte E, Etard JF. Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea. Clin Infect Dis 2018; 64:1788-1790. [PMID: 28329169 DOI: 10.1093/cid/cix210] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Accepted: 03/07/2017] [Indexed: 11/13/2022] Open
Abstract
This study modeled the presence of Ebola virus RNA in the semen of male Ebola survivors participating in the Postebogui study in Guinea. The median time of reverse-transcription polymerase chain reaction negativity was 46.4 days after symptom onset (95% confidence interval, 11-82.6). The results emphasize the importance of the World Health Organization recommendations for survivors' management.
Collapse
Affiliation(s)
- Fabien Subtil
- Institut de Recherche pour le Développement (IRD) UMI 233, Institut National de la Santé et de la Recherche Médicale (INSERM) U1175, Montpellier University.,Hospices Civils de Lyon, Service de Biostatistique, Lyon, and.,CNRS UMR 5558 Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Villeurbanne, France
| | - Charlotte Delaunay
- Institut de Recherche pour le Développement (IRD) UMI 233, Institut National de la Santé et de la Recherche Médicale (INSERM) U1175, Montpellier University.,Hospices Civils de Lyon, Service de Biostatistique, Lyon, and.,CNRS UMR 5558 Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Villeurbanne, France
| | - Alpha Kabinet Keita
- Institut de Recherche pour le Développement (IRD) UMI 233, Institut National de la Santé et de la Recherche Médicale (INSERM) U1175, Montpellier University
| | | | - Abdoulaye Touré
- Institut de Recherche pour le Développement (IRD) UMI 233, Institut National de la Santé et de la Recherche Médicale (INSERM) U1175, Montpellier University.,Chaire de Santé Publique, Département de Pharmacie, Université de Conakry, and
| | - Sandrine Leroy
- Institut de Recherche pour le Développement (IRD) UMI 233, Institut National de la Santé et de la Recherche Médicale (INSERM) U1175, Montpellier University
| | - Philippe Msellati
- Institut de Recherche pour le Développement (IRD) UMI 233, Institut National de la Santé et de la Recherche Médicale (INSERM) U1175, Montpellier University
| | - N'Fally Magassouba
- Projet des fièvres hémorragiques de Guinée, Donka National Hospital, Conakry, Guinea
| | - Sylvain Baize
- Pasteur Institute/Unit of Biology of Emerging Viral Infections, International Center for Infectiology Research, INSERM, CNRS, Lyon I University, Ecole Normale Supérieure de Lyon, and
| | - Hervé Raoul
- Laboratoire P4 Inserm-Jean Mérieux, US003 INSERM, Lyon,France
| | - René Ecochard
- Hospices Civils de Lyon, Service de Biostatistique, Lyon, and.,CNRS UMR 5558 Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Villeurbanne, France
| | - Moumié Barry
- Infectious Diseases Department, Donka University National Hospital
| | - Eric Delaporte
- Institut de Recherche pour le Développement (IRD) UMI 233, Institut National de la Santé et de la Recherche Médicale (INSERM) U1175, Montpellier University
| | - Jean-François Etard
- Institut de Recherche pour le Développement (IRD) UMI 233, Institut National de la Santé et de la Recherche Médicale (INSERM) U1175, Montpellier University
| | | |
Collapse
|
28
|
Dowall SD, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, Al Abdulla I, Hewson R, Carroll MW. Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product. Sci Rep 2017. [PMID: 28642489 PMCID: PMC5481440 DOI: 10.1038/s41598-017-03910-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Despite sporadic outbreaks of Ebola virus (EBOV) over the last 4 decades and the recent public health emergency in West Africa, there are still no approved vaccines or therapeutics for the treatment of acute EBOV disease (EVD). In response to the 2014 outbreak, an ovine immunoglobulin therapy was developed, termed EBOTAb. After promising results in the guinea pig model of EBOV infection, EBOTAb was tested in the cynomolgus macaque non-human primate model of lethal EBOV infection. To ensure stringent therapeutic testing conditions to replicate likely clinical usage, EBOTAb was first delivered 1, 2 or 3 days post-challenge with a lethal dose of EBOV. Results showed a protective effect of EBOTAb given post-exposurally, with survival rates decreasing with increasing time after challenge. Viremia results demonstrated that EBOTAb resulted in a decreased circulation of EBOV in the bloodstream. Additionally, assay of liver enzymes and histology analysis of local tissues identified differences between EBOTAb-treated and untreated groups. The results presented demonstrate that EBOTAb conferred protection against EBOV when given post-exposure and should be explored and developed further as a potential intervention strategy for future outbreaks, which are likely to occur.
Collapse
Affiliation(s)
- Stuart D Dowall
- National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK
| | - Frédéric Jacquot
- Laboratoire P4, INSERM Jean Merieux, 21 Avenue Tony Garnier, Lyon, France
| | - John Landon
- MicroPharm Ltd, Station Road, Newcastle Emlyn, Dyfed, SA38 9BY, UK
| | - Emma Rayner
- National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK
| | - Graham Hall
- National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK
| | | | - Hervé Raoul
- Laboratoire P4, INSERM Jean Merieux, 21 Avenue Tony Garnier, Lyon, France
| | - Delphine Pannetier
- Laboratoire P4, INSERM Jean Merieux, 21 Avenue Tony Garnier, Lyon, France
| | - Ian Cameron
- MicroPharm Ltd, Station Road, Newcastle Emlyn, Dyfed, SA38 9BY, UK
| | - Ruth Coxon
- MicroPharm Ltd, Station Road, Newcastle Emlyn, Dyfed, SA38 9BY, UK
| | | | - Roger Hewson
- National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK
| | - Miles W Carroll
- National Infection Service, Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
| |
Collapse
|
29
|
Keita A, Toure A, Sow M, Raoul H, Magassouba N, Delaporte E, Etard JF, Abel L, Ayouba A, Baize S, Bangoura K, Barry A, Barry M, Cissé M, Delaporte E, Delmas C, Desclaux A, Diallo S, Diallo M, Diallo M, Étard JF, Etienne C, Faye O, Fofana I, Granouillac B, Hébert E, Izard S, Kassé D, Keita A, Koivugui L, Kpamou C, Lacarabaratz C, Leroy S, Marchal C, Levy Y, Magassouba N, March L, Msellati P, Niane H, Peeters M, Pers YM, Raoul H, Sacko S, Savané I, Sow M, Taverne B, Touré A, Traoré F. Extraordinary long-term and fluctuating persistence of Ebola virus RNA in semen of survivors in Guinea: implications for public health. Clin Microbiol Infect 2017; 23:412-413. [DOI: 10.1016/j.cmi.2016.11.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2016] [Revised: 09/01/2016] [Accepted: 11/02/2016] [Indexed: 11/16/2022]
|
30
|
Hereth-Hebert E, Bah MO, Etard JF, Sow MS, Resnikoff S, Fardeau C, Toure A, Ouendeno AN, Sagno IC, March L, Izard S, Lama PL, Barry M, Delaporte E, Ayouba A, Baize S, Barry M, Camara A, Cissé M, Delaporte E, Delfraissy JF, Delmas C, Desclaux A, Diallo SB, Diallo MS, Étard JF, Etienne C, Granouillac B, Izard S, Kassé D, Keita AK, Keita S, Hébert EH, Koivugui L, Kpamou C, Lacarabaratz C, Leroy S, Marchal CL, Levy Y, Magassouba N, March L, Peeters M, Raoul H, Savané I, Sow MS, Taverne B, Touré A, Yazdanpanah Y. Ocular Complications in Survivors of the Ebola Outbreak in Guinea. Am J Ophthalmol 2017; 175:114-121. [PMID: 27998698 DOI: 10.1016/j.ajo.2016.12.005] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Revised: 12/05/2016] [Accepted: 12/07/2016] [Indexed: 12/17/2022]
Abstract
PURPOSE The Ebola outbreak of 2013-2016 severely affected West Africa and resulted in 2544 deaths and 1270 survivors in Guinea, the country where it began. This Ebola virus was the Zaire strain of the virus family Filoviridae. In this outbreak the case fatality rate was about 67%. The survivors, declared cured after 2 negative blood polymerase chain reaction (PCR) results, face psychosocial disorders and rheumatic, ear-nose-throat, neurocognitive, and ophthalmologic complications. The goal of this study was to detect and describe ocular complications afflicting these survivors and to observe their occurrence and recurrences. DESIGN Prospective observational cohort study. METHODS This prospective observational multicenter cohort study was initiated in March 2015. The cohort study included 341 survivors followed up in the infectious disease ward of Conakry, Forecariah, and Nzérékoré as of May 2016. The patients received multidisciplinary medical follow-up expected to last at least 1 year that included an eye examination as part of complete, free treatment. RESULTS Systematic examination of 341 patients revealed 46 cases of uveitis (13.5%), 6 cases of episcleritis (1.8%), and 3 cases of interstitial keratitis (0.9%). Uveitis was most frequently unilateral (78.3%) and anterior (47.8%) and occurred within the 2 months after discharge from the Ebola treatment center. Moreover, uveitis relapses were found up to 13 months after the negative PCR result for Ebola in the blood. CONCLUSION Nearly 1 out of 6 survivors presented ocular disorders after discharge from the Ebola treatment center. An ophthalmologic follow-up for Ebola-infected patients should start, if possible, during the acute phase of the disease and last more than 1 year. Treatment guidelines need to be urgently developed and implemented.
Collapse
|
31
|
Etard JF, Sow MS, Leroy S, Touré A, Taverne B, Keita AK, Msellati P, Magassouba N, Baize S, Raoul H, Izard S, Kpamou C, March L, Savane I, Barry M, Delaporte E. Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. Lancet Infect Dis 2017; 17:545-552. [PMID: 28094208 DOI: 10.1016/s1473-3099(16)30516-3] [Citation(s) in RCA: 84] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Revised: 11/02/2016] [Accepted: 11/21/2016] [Indexed: 11/17/2022]
Abstract
BACKGROUND The high number of survivors from the 2013-16 west African outbreak of Ebola virus disease (EVD) has raised several new issues: long-term clinical complications, psychosocial consequences, risks of EVD reactivation, and secondary transmission due to viral persistence in body fluids. We aimed to assess long-term clinical, psychosocial, and viral outcomes in EVD survivors in Guinea. METHODS In this multidisciplinary observational cohort study, we recruited patients aged 1 year or more in four sites in Guinea (Donka National Hospital, Conakry; Macenta Prefectoral Hospital, Macenta; N'zérékoré Regional Hospital, N'zérékoré; and Forécariah Prefectoral Hospital, Forécariah) following discharge from any Ebola treatment centre in Guinea. Eligible patients had had laboratory-confirmed EVD and had then been declared clear of the virus in the blood. All consenting patients were included, with no exclusion criteria. Trained clinicians assessed patients at enrolment to the cohort, recording clinical symptoms and signs of depression. We did routine blood examinations and examined viral persistence in body fluids using RT-PCR. We did psychological evaluations using questionnaires developed for different age groups. Follow-up is planned to 2 years, and here we present findings at enrolment. FINDINGS Between March 23, 2015, and July 11, 2016, we recruited 802 patients, of whom 360 (45%) were male, 442 (55%) were female; 158 (20%) were younger than 18 years. The median age was 28·4 years (range 1·0-79·9, IQR 19·4-39·8). The median delay after discharge was 350 days (IQR 223-491). The most frequent symptoms were general symptoms (324 [40%] patients), musculoskeletal pain (303 [38%]), headache (278 [35%]), depression (124 [17%] of 713 responses), abdominal pain (178 [22%]), and ocular disorders (142 [18%]). More adults than children had at least one clinical symptom (505 [78%] vs 101 [64%], p<0·0003), ocular complications (124 [19%] vs 18 [11%], p=0·0200), or musculoskeletal symptoms (274 [43%] vs 29 [18%], p<0·0001). A positive RT-PCR in semen was found in ten (5%) of 188 men, at a maximum of 548 days after disease onset. 204 (26%) of 793 patients reported stigmatisation. Ocular complications were more frequent at enrolment than at discharge (142 [18%] vs 61 [8%] patients). INTERPRETATION Post-EVD symptoms can remain long after recovery and long-term viral persistence in semen is confirmed. The results justify calls for regular check-ups of survivors at least 18 months after recovery. FUNDING INSERM/Reacting, the French Ebola Task Force, and Institut de Recherche pour le Développement.
Collapse
Affiliation(s)
| | | | - Sandrine Leroy
- IRD UMI 233-INSERM U1175-Montpellier University, Montpellier, France; Episcience, London, UK
| | - Abdoulaye Touré
- IRD UMI 233-INSERM U1175-Montpellier University, Montpellier, France; Conakry University, Department of Public Health, Conakry, Guinea
| | - Bernard Taverne
- IRD UMI 233-INSERM U1175-Montpellier University, Montpellier, France
| | | | - Philippe Msellati
- IRD UMI 233-INSERM U1175-Montpellier University, Montpellier, France
| | | | - Sylvain Baize
- Pasteur Institute/Unit of Biology of Emerging Viral Infections, International Center for Infectiology Research, INSERM, CNRS, Lyon I University, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Hervé Raoul
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, Lyon, France
| | - Suzanne Izard
- IRD UMI 233-INSERM U1175-Montpellier University, Montpellier, France
| | - Cécé Kpamou
- IRD UMI 233-INSERM U1175-Montpellier University, Montpellier, France
| | - Laura March
- IRD UMI 233-INSERM U1175-Montpellier University, Montpellier, France
| | | | | | - Eric Delaporte
- IRD UMI 233-INSERM U1175-Montpellier University, Montpellier, France.
| |
Collapse
|
32
|
Reynard O, Jacquot F, Evanno G, Mai HL, Salama A, Martinet B, Duvaux O, Bach JM, Conchon S, Judor JP, Perota A, Lagutina I, Duchi R, Lazzari G, Le Berre L, Perreault H, Lheriteau E, Raoul H, Volchkov V, Galli C, Soulillou JP. Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs. PLoS One 2016; 11:e0156775. [PMID: 27280712 PMCID: PMC4900587 DOI: 10.1371/journal.pone.0156775] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Accepted: 05/19/2016] [Indexed: 01/13/2023] Open
Abstract
Polyclonal xenogenic IgGs, although having been used in the prevention and cure of severe infectious diseases, are highly immunogenic, which may restrict their usage in new applications such as Ebola hemorrhagic fever. IgG glycans display powerful xenogeneic antigens in humans, for example α1–3 Galactose and the glycolyl form of neuraminic acid Neu5Gc, and IgGs deprived of these key sugar epitopes may represent an advantage for passive immunotherapy. In this paper, we explored whether low immunogenicity IgGs had a protective effect on a guinea pig model of Ebola virus (EBOV) infection. For this purpose, a double knock-out pig lacking α1–3 Galactose and Neu5Gc was immunized against virus-like particles displaying surface EBOV glycoprotein GP. Following purification from serum, hyper-immune polyclonal IgGs were obtained, exhibiting an anti-EBOV GP titer of 1:100,000 and a virus neutralizing titer of 1:100. Guinea pigs were injected intramuscularly with purified IgGs on day 0 and day 3 post-EBOV infection. Compared to control animals treated with IgGs from non-immunized double KO pigs, the anti-EBOV IgGs-treated animals exhibited a significantly prolonged survival and a decreased virus load in blood on day 3. The data obtained indicated that IgGs lacking α1–3 Galactose and Neu5Gc, two highly immunogenic epitopes in humans, have a protective effect upon EBOV infection.
Collapse
Affiliation(s)
- Olivier Reynard
- Molecular Basis of Viral Pathogenicity, CIRI, INSERM U1111—CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale supérieure de Lyon, Lyon, France
| | | | | | - Hoa Le Mai
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Nantes, France
| | | | - Bernard Martinet
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Nantes, France
| | | | - Jean-Marie Bach
- Xenothera, Nantes, France
- IECM, EA4644 Université de Nantes, ONIRIS, USC1383 INRA, Nantes, France
| | - Sophie Conchon
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Nantes, France
| | - Jean-Paul Judor
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Nantes, France
| | - Andrea Perota
- Avantea, Laboratory of Reproductive Technologies, Cremona, Italy
| | - Irina Lagutina
- Avantea, Laboratory of Reproductive Technologies, Cremona, Italy
| | - Roberto Duchi
- Avantea, Laboratory of Reproductive Technologies, Cremona, Italy
| | - Giovanna Lazzari
- Avantea, Laboratory of Reproductive Technologies, Cremona, Italy
- Avantea Foundation, Cremona, Italy
| | - Ludmilla Le Berre
- INSERM, UMR 1064, Nantes, France
- CHU de Nantes, ITUN, Nantes, France
- Université de Nantes, Nantes, France
| | | | | | - Hervé Raoul
- Inserm-Jean Mérieux BSL4 Laboratory, US003 Inserm, Lyon, France
- * E-mail: (JPS); (VV); ; (HR)
| | - Viktor Volchkov
- Molecular Basis of Viral Pathogenicity, CIRI, INSERM U1111—CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale supérieure de Lyon, Lyon, France
- * E-mail: (JPS); (VV); ; (HR)
| | - Cesare Galli
- Avantea, Laboratory of Reproductive Technologies, Cremona, Italy
- Avantea Foundation, Cremona, Italy
- Department of Veterinary Medical Sciences, University of Bologna, Ozzano Emilia, Italy
- * E-mail: (JPS); (VV); ; (HR)
| | - Jean-Paul Soulillou
- Xenothera, Nantes, France
- Université de Nantes, Nantes, France
- * E-mail: (JPS); (VV); ; (HR)
| |
Collapse
|
33
|
Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D. Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med 2016; 13:e1002009. [PMID: 27046271 PMCID: PMC4821578 DOI: 10.1371/journal.pmed.1002009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
[This corrects the article DOI: 10.1371/journal.pmed.1001967.].
Collapse
|
34
|
van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Weggheleire A, Haba N. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med 2016; 374:33-42. [PMID: 26735992 PMCID: PMC5856332 DOI: 10.1056/nejmoa1511812] [Citation(s) in RCA: 377] [Impact Index Per Article: 47.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries, the World Health Organization prioritized the evaluation of treatment with convalescent plasma derived from patients who have recovered from the disease. We evaluated the safety and efficacy of convalescent plasma for the treatment of EVD in Guinea. METHODS In this nonrandomized, comparative study, 99 patients of various ages (including pregnant women) with confirmed EVD received two consecutive transfusions of 200 to 250 ml of ABO-compatible convalescent plasma, with each unit of plasma obtained from a separate convalescent donor. The transfusions were initiated on the day of diagnosis or up to 2 days later. The level of neutralizing antibodies against Ebola virus in the plasma was unknown at the time of administration. The control group was 418 patients who had been treated at the same center during the previous 5 months. The primary outcome was the risk of death during the period from 3 to 16 days after diagnosis with adjustments for age and the baseline cycle-threshold value on polymerase-chain-reaction assay; patients who had died before day 3 were excluded. The clinically important difference was defined as an absolute reduction in mortality of 20 percentage points in the convalescent-plasma group as compared with the control group. RESULTS A total of 84 patients who were treated with plasma were included in the primary analysis. At baseline, the convalescent-plasma group had slightly higher cycle-threshold values and a shorter duration of symptoms than did the control group, along with a higher frequency of eye redness and difficulty in swallowing. From day 3 to day 16 after diagnosis, the risk of death was 31% in the convalescent-plasma group and 38% in the control group (risk difference, -7 percentage points; 95% confidence interval [CI], -18 to 4). The difference was reduced after adjustment for age and cycle-threshold value (adjusted risk difference, -3 percentage points; 95% CI, -13 to 8). No serious adverse reactions associated with the use of convalescent plasma were observed. CONCLUSIONS The transfusion of up to 500 ml of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed EVD was not associated with a significant improvement in survival. (Funded by the European Union's Horizon 2020 Research and Innovation Program and others; ClinicalTrials.gov number, NCT02342171.).
Collapse
Affiliation(s)
- Johan van Griensven
- From the Institute of Tropical Medicine, Antwerp (J.G., K.F., J.B., R.R., Y.C., M.D.C., L.L., A.D.W.), Médecins sans Frontières, Brussels (A.A., C.L.), and the Clinical Pharmacology and Pharmacotherapy Department, Katholieke Universiteit Leuven, Leuven (R.R.) - all in Belgium; Medical Research Council Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London (T.E., P.G.S.), Institute of Translational Medicine and National Institute for Health Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool (M.G.S.), and Centre for Tropical Medicine and Global Health, University of Oxford, Oxford (P.W.H.) - all in the United Kingdom; Aix Marseille University (X.L., P.G.), French Institute of Research for Development (X.L.), École des Hautes Études en Santé Publique (X.L.), and Institut Hospitalo-Universitaire Méditerranée Infection (X.L., P.G.), Marseille, Etablissement Français du Sang, La Plaine Saint Denis (P.G., P.T.), Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Centre International de Recherche en Infectiologie (S.B.), Laboratoire P4 INSERM-Jean Mérieux (H.R.), Lyon, and Université de Franche Comté, Etablissement Français du Sang, INSERM UMR 1098, Besançon (P.T.) - all in France; Laboratory of Viral Hemorrhagic Fever, Gamal Abdel Nasser University of Conakry (N.M.), Service des Maladies Infectieuses et Tropicales de l'Hôpital National Donka, Conakry (E.I.B.), National Blood Transfusion Center (N.H.), Conakry, and National Center for Training and Research in Rural Health of Maferinyah, Forecariah (A.D.) - all in Guinea; and Institut Pasteur de Dakar, Dakar, Senegal (O.F., A.A.S.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Carroll MW, Matthews DA, Hiscox JA, Elmore MJ, Pollakis G, Rambaut A, Hewson R, García-Dorival I, Bore JA, Koundouno R, Abdellati S, Afrough B, Aiyepada J, Akhilomen P, Asogun D, Atkinson B, Badusche M, Bah A, Bate S, Baumann J, Becker D, Becker-Ziaja B, Bocquin A, Borremans B, Bosworth A, Boettcher JP, Cannas A, Carletti F, Castilletti C, Clark S, Colavita F, Diederich S, Donatus A, Duraffour S, Ehichioya D, Ellerbrok H, Fernandez-Garcia MD, Fizet A, Fleischmann E, Gryseels S, Hermelink A, Hinzmann J, Hopf-Guevara U, Ighodalo Y, Jameson L, Kelterbaum A, Kis Z, Kloth S, Kohl C, Korva M, Kraus A, Kuisma E, Kurth A, Liedigk B, Logue CH, Lüdtke A, Maes P, McCowen J, Mély S, Mertens M, Meschi S, Meyer B, Michel J, Molkenthin P, Muñoz-Fontela C, Muth D, Newman ENC, Ngabo D, Oestereich L, Okosun J, Olokor T, Omiunu R, Omomoh E, Pallasch E, Pályi B, Portmann J, Pottage T, Pratt C, Priesnitz S, Quartu S, Rappe J, Repits J, Richter M, Rudolf M, Sachse A, Schmidt KM, Schudt G, Strecker T, Thom R, Thomas S, Tobin E, Tolley H, Trautner J, Vermoesen T, Vitoriano I, Wagner M, Wolff S, Yue C, Capobianchi MR, Kretschmer B, Hall Y, Kenny JG, Rickett NY, Dudas G, Coltart CEM, Kerber R, Steer D, Wright C, Senyah F, Keita S, Drury P, Diallo B, de Clerck H, Van Herp M, Sprecher A, Traore A, Diakite M, Konde MK, Koivogui L, Magassouba N, Avšič-Županc T, Nitsche A, Strasser M, Ippolito G, Becker S, Stoecker K, Gabriel M, Raoul H, Di Caro A, Wölfel R, Formenty P, Günther S. Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa. Nature 2015; 524:97-101. [PMID: 26083749 PMCID: PMC10601607 DOI: 10.1038/nature14594] [Citation(s) in RCA: 216] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Accepted: 06/01/2015] [Indexed: 01/17/2023]
Abstract
West Africa is currently witnessing the most extensive Ebola virus (EBOV) outbreak so far recorded. Until now, there have been 27,013 reported cases and 11,134 deaths. The origin of the virus is thought to have been a zoonotic transmission from a bat to a two-year-old boy in December 2013 (ref. 2). From this index case the virus was spread by human-to-human contact throughout Guinea, Sierra Leone and Liberia. However, the origin of the particular virus in each country and time of transmission is not known and currently relies on epidemiological analysis, which may be unreliable owing to the difficulties of obtaining patient information. Here we trace the genetic evolution of EBOV in the current outbreak that has resulted in multiple lineages. Deep sequencing of 179 patient samples processed by the European Mobile Laboratory, the first diagnostics unit to be deployed to the epicentre of the outbreak in Guinea, reveals an epidemiological and evolutionary history of the epidemic from March 2014 to January 2015. Analysis of EBOV genome evolution has also benefited from a similar sequencing effort of patient samples from Sierra Leone. Our results confirm that the EBOV from Guinea moved into Sierra Leone, most likely in April or early May. The viruses of the Guinea/Sierra Leone lineage mixed around June/July 2014. Viral sequences covering August, September and October 2014 indicate that this lineage evolved independently within Guinea. These data can be used in conjunction with epidemiological information to test retrospectively the effectiveness of control measures, and provides an unprecedented window into the evolution of an ongoing viral haemorrhagic fever outbreak.
Collapse
Affiliation(s)
- Miles W. Carroll
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- University of Southampton, South General Hospital, Southampton, SO16 6YD UK
| | - David A. Matthews
- Department of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, Bristol, BS8 1TD UK
| | - Julian A. Hiscox
- Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 2BE UK
| | | | - Georgios Pollakis
- Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 2BE UK
| | - Andrew Rambaut
- Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, EH9 2FL UK
- Fogarty International Center, National Institutes of Health, Bethesda, 20892 Maryland USA
- Centre for Immunology, Infection and Evolution, University of Edinburgh, Edinburgh, EH9 2FL UK
| | - Roger Hewson
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT UK
| | - Isabel García-Dorival
- Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 2BE UK
| | - Joseph Akoi Bore
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Université Gamal Abdel Nasser de Conakry, Laboratoire des Fièvres Hémorragiques en Guinée, Conakry, Guinea
- Institut National de Santé Publique, Conakry, Guinea
| | - Raymond Koundouno
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Université Gamal Abdel Nasser de Conakry, Laboratoire des Fièvres Hémorragiques en Guinée, Conakry, Guinea
- Institut National de Santé Publique, Conakry, Guinea
| | - Saïd Abdellati
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Tropical Medicine, Antwerp, B-2000 Belgium
| | - Babak Afrough
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - John Aiyepada
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Patience Akhilomen
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Danny Asogun
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Barry Atkinson
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Marlis Badusche
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Amadou Bah
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Swiss Tropical and Public Health Institute, University of Basel, Basel, CH-4002 Switzerland
| | - Simon Bate
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Jan Baumann
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Dirk Becker
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, Philipps University Marburg, Marburg, 35043 Germany
| | - Beate Becker-Ziaja
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Anne Bocquin
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, 69365 France
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, Lyon, 69365 France
| | - Benny Borremans
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Department of Biology, University of Antwerp, Antwerp, B-2020 Belgium
| | - Andrew Bosworth
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 2BE UK
| | - Jan Peter Boettcher
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Angela Cannas
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Fabrizio Carletti
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Concetta Castilletti
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Simon Clark
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Francesca Colavita
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Sandra Diederich
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Friedrich Loeffler Institute, Federal Research Institute for Animal Health, Greifswald, 17493 Insel Riems Germany
| | - Adomeh Donatus
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Sophie Duraffour
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- KU Leuven Rega institute, Leuven, B-3000 Belgium
| | - Deborah Ehichioya
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Redeemer’s University, Osun State Nigeria
| | - Heinz Ellerbrok
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Maria Dolores Fernandez-Garcia
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, 28029 Spain
| | - Alexandra Fizet
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, 69365 France
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, 69365 France
| | - Erna Fleischmann
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Bundeswehr Institute of Microbiology, Munich, 80937 Germany
| | - Sophie Gryseels
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Department of Biology, University of Antwerp, Antwerp, B-2020 Belgium
| | - Antje Hermelink
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Julia Hinzmann
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Ute Hopf-Guevara
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Yemisi Ighodalo
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Lisa Jameson
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Anne Kelterbaum
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, Philipps University Marburg, Marburg, 35043 Germany
| | - Zoltan Kis
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Center for Epidemiology, National Biosafety Laboratory, Budapest, H-1097 Hungary
| | - Stefan Kloth
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Claudia Kohl
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Miša Korva
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, SI-1000 Slovenia
| | - Annette Kraus
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Public Health Agency of Sweden, Solna, 171 82 Sweden
| | - Eeva Kuisma
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Andreas Kurth
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Britta Liedigk
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Christopher H. Logue
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Anja Lüdtke
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Heinrich Pette Institute – Leibniz Institute for Experimental Virology, Hamburg, 20251 Germany
| | - Piet Maes
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- KU Leuven Rega institute, Leuven, B-3000 Belgium
| | - James McCowen
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Stéphane Mély
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, 69365 France
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, Lyon, 69365 France
| | - Marc Mertens
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Friedrich Loeffler Institute, Federal Research Institute for Animal Health, Greifswald, 17493 Insel Riems Germany
| | - Silvia Meschi
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Benjamin Meyer
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, University of Bonn, Bonn, 53127 Germany
| | - Janine Michel
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Peter Molkenthin
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Bundeswehr Institute of Microbiology, Munich, 80937 Germany
| | - César Muñoz-Fontela
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Heinrich Pette Institute – Leibniz Institute for Experimental Virology, Hamburg, 20251 Germany
| | - Doreen Muth
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, University of Bonn, Bonn, 53127 Germany
| | - Edmund N. C. Newman
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Didier Ngabo
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Lisa Oestereich
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Jennifer Okosun
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Thomas Olokor
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Racheal Omiunu
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Emmanuel Omomoh
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Elisa Pallasch
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Bernadett Pályi
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Center for Epidemiology, National Biosafety Laboratory, Budapest, H-1097 Hungary
| | - Jasmine Portmann
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Federal Office for Civil Protection, Spiez Laboratory, Spiez, CH-3700 Switzerland
| | - Thomas Pottage
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Catherine Pratt
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Simone Priesnitz
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bundeswehr Hospital, Hamburg, 22049 Germany
| | - Serena Quartu
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Julie Rappe
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Virology and Immunology, Mittelhäusern, CH-3147 Switzerland
| | - Johanna Repits
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Janssen-Cilag, Sollentuna, SE-192 07 Sweden
| | - Martin Richter
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Martin Rudolf
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Andreas Sachse
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Kristina Maria Schmidt
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Gordian Schudt
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, Philipps University Marburg, Marburg, 35043 Germany
| | - Thomas Strecker
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, Philipps University Marburg, Marburg, 35043 Germany
| | - Ruth Thom
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Stephen Thomas
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Ekaete Tobin
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Howard Tolley
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Jochen Trautner
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Thünen Institute, Hamburg, D-22767 Germany
| | - Tine Vermoesen
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Tropical Medicine, Antwerp, B-2000 Belgium
| | - Inês Vitoriano
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Matthias Wagner
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Bundeswehr Institute of Microbiology, Munich, 80937 Germany
| | - Svenja Wolff
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, Philipps University Marburg, Marburg, 35043 Germany
| | - Constanze Yue
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Maria Rosaria Capobianchi
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Birte Kretschmer
- Eurice - European Research and Project Office GmbH, Berlin, 10115 Germany
| | - Yper Hall
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
| | - John G. Kenny
- Centre for Genomic Research, Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB UK
| | - Natasha Y. Rickett
- Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 2BE UK
| | - Gytis Dudas
- Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, EH9 2FL UK
| | - Cordelia E. M. Coltart
- Department of Infection and Population Health, University College London, London, WC1E 6JB UK
| | - Romy Kerber
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Damien Steer
- Research IT, University of Bristol, Bristol, BS8 1HH UK
| | - Callum Wright
- Advanced Computing Research Centre, University of Bristol, Bristol, BS8 1HH UK
| | - Francis Senyah
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
| | | | - Patrick Drury
- World Health Organization, Geneva 27, 1211 Switzerland
| | | | | | | | | | - Alexis Traore
- Section Prévention et Lutte contre la Maladie à la Direction Préfectorale de la Santé de Guéckédou, Guéckédou, Guinea
| | - Mandiou Diakite
- Université Gamal Abdel Nasser de Conakry, CHU Donka, Conakry, Guinea
| | | | | | - N’Faly Magassouba
- Université Gamal Abdel Nasser de Conakry, Laboratoire des Fièvres Hémorragiques en Guinée, Conakry, Guinea
| | - Tatjana Avšič-Županc
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, SI-1000 Slovenia
| | - Andreas Nitsche
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Marc Strasser
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Federal Office for Civil Protection, Spiez Laboratory, Spiez, CH-3700 Switzerland
| | - Giuseppe Ippolito
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Stephan Becker
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, Philipps University Marburg, Marburg, 35043 Germany
| | - Kilian Stoecker
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Bundeswehr Institute of Microbiology, Munich, 80937 Germany
| | - Martin Gabriel
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Hervé Raoul
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, Lyon, 69365 France
| | - Antonino Di Caro
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Roman Wölfel
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Bundeswehr Institute of Microbiology, Munich, 80937 Germany
| | | | - Stephan Günther
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| |
Collapse
|
36
|
Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolié M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Günther S. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371:1418-25. [PMID: 24738640 DOI: 10.1056/nejmoa1404505] [Citation(s) in RCA: 910] [Impact Index Per Article: 91.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
In March 2014, the World Health Organization was notified of an outbreak of a communicable disease characterized by fever, severe diarrhea, vomiting, and a high fatality rate in Guinea. Virologic investigation identified Zaire ebolavirus (EBOV) as the causative agent. Full-length genome sequencing and phylogenetic analysis showed that EBOV from Guinea forms a separate clade in relationship to the known EBOV strains from the Democratic Republic of Congo and Gabon. Epidemiologic investigation linked the laboratory-confirmed cases with the presumed first fatality of the outbreak in December 2013. This study demonstrates the emergence of a new EBOV strain in Guinea.
Collapse
Affiliation(s)
- Sylvain Baize
- The authors' affiliations are listed in the Appendix
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Herbreteau CH, Jacquot F, Rith S, Vacher L, Nguyen L, Carbonnelle C, Lotteau V, Jolivet M, Raoul H, Buchy P, Saluzzo JF. Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice. Immunotherapy 2014; 6:699-708. [PMID: 24673720 DOI: 10.2217/imt.14.40] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
AIM There is still no specific therapy for infection with the highly pathogenic avian influenza A virus (HPAI) H5N1, which caused 39 human cases with a 64% fatality rate in 2013. MATERIALS & METHODS We prepared highly purified specific equine polyclonal immunoglobulin fragments (F(ab')2) against H5N1 and tested them for efficacy in vitro and with different administration schedules in H5N1-challenged BALB/c mice. RESULTS in vitro, F(ab')2 neutralized 21 different H5N1 strains from different areas, representative of 11 different clades and sub-clades and 9 years of evolution of the virus. In vivo mouse experiments identified that the most efficient administration protocol consists of five consecutive daily injections after infection; 10 mg/kg giving a 60% increase in survival. CONCLUSION These data demonstrate the ability of anti-H5N1 F(ab')2 to markedly reduce the mortality and morbidity associated with infection of mice with HPAI H5N1 virus, and their potential for human therapy.
Collapse
|
38
|
Yoneda M, Georges-Courbot MC, Ikeda F, Ishii M, Nagata N, Jacquot F, Raoul H, Sato H, Kai C. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PLoS One 2013; 8:e58414. [PMID: 23516477 PMCID: PMC3597623 DOI: 10.1371/journal.pone.0058414] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2012] [Accepted: 02/04/2013] [Indexed: 11/21/2022] Open
Abstract
Nipah virus (NiV) is a member of the genus Henipavirus, which emerged in Malaysia in 1998. In pigs, infection resulted in a predominantly non-lethal respiratory disease; however, infection in humans resulted in over 100 deaths. Nipah virus has continued to re-emerge in Bangladesh and India, and person-to-person transmission appeared in the outbreak. Although a number of NiV vaccine studies have been reported, there are currently no vaccines or treatments licensed for human use. In this study, we have developed a recombinant measles virus (rMV) vaccine expressing NiV envelope glycoproteins (rMV-HL-G and rMV-Ed-G). Vaccinated hamsters were completely protected against NiV challenge, while the mortality of unvaccinated control hamsters was 90%. We trialed our vaccine in a non-human primate model, African green monkeys. Upon intraperitoneal infection with NiV, monkeys showed several clinical signs of disease including severe depression, reduced ability to move and decreased food ingestion and died at 7 days post infection (dpi). Intranasal and oral inoculation induced similar clinical illness in monkeys, evident around 9 dpi, and resulted in a moribund stage around 14 dpi. Two monkeys immunized subcutaneously with rMV-Ed-G showed no clinical illness prior to euthanasia after challenge with NiV. Viral RNA was not detected in any organ samples collected from vaccinated monkeys, and no pathological changes were found upon histopathological examination. From our findings, we propose that rMV-NiV-G is an appropriate NiV vaccine candidate for use in humans.
Collapse
Affiliation(s)
- Misako Yoneda
- Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
- * E-mail: (MY); (CK)
| | | | - Fusako Ikeda
- Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
| | - Miho Ishii
- Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
| | - Noriyo Nagata
- National Institute of Infectious Diseases, Department of Pathology Tokyo, Japan
| | - Frederic Jacquot
- Institut National de la Sante et de la Recherche Médicale, Laboratory P4 INSERM Jean Mérieux, Lyon, France
| | - Hervé Raoul
- Institut National de la Sante et de la Recherche Médicale, Laboratory P4 INSERM Jean Mérieux, Lyon, France
| | - Hiroki Sato
- Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
| | - Chieko Kai
- Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
- International Research Center for Infectious Diseases, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
- * E-mail: (MY); (CK)
| |
Collapse
|
39
|
Nisii C, Castilletti C, Raoul H, Hewson R, Brown D, Gopal R, Eickmann M, Gunther S, Mirazimi A, Koivula T, Feldmann H, Di Caro A, Capobianchi MR, Ippolito G. Biosafety Level-4 laboratories in Europe: opportunities for public health, diagnostics, and research. PLoS Pathog 2013; 9:e1003105. [PMID: 23349630 PMCID: PMC3547859 DOI: 10.1371/journal.ppat.1003105] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Carla Nisii
- “L. Spallanzani” National Institute for Infectious Diseases, Rome, Italy
| | | | - Hervé Raoul
- French National Institute for Health and Medical Research, Lyon, France
| | - Roger Hewson
- Health Protection Agency, Salisbury, United Kingdom
| | - David Brown
- Health Protection Agency, London, United Kingdom
| | - Robin Gopal
- Health Protection Agency, London, United Kingdom
| | | | - Stephan Gunther
- Bernhard Nocht Institute of Tropical Medicine, Hamburg, Germany
| | - Ali Mirazimi
- Swedish Institute for Communicable Disease Control, Solna, Sweden
| | - Tuija Koivula
- Swedish Institute for Communicable Disease Control, Solna, Sweden
| | - Heinz Feldmann
- Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) Rocky Mountain Laboratories, Hamilton, Montana, United States of America
| | - Antonino Di Caro
- “L. Spallanzani” National Institute for Infectious Diseases, Rome, Italy
| | | | - Giuseppe Ippolito
- “L. Spallanzani” National Institute for Infectious Diseases, Rome, Italy
| |
Collapse
|
40
|
Dhondt KP, Mathieu C, Chalons M, Reynaud JM, Vallve A, Raoul H, Horvat B. Type I interferon signaling protects mice from lethal henipavirus infection. J Infect Dis 2012; 207:142-51. [PMID: 23089589 PMCID: PMC7107294 DOI: 10.1093/infdis/jis653] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Hendra virus (HeV) and Nipah virus (NiV) are closely related, recently emerged paramyxoviruses that form Henipavirus genus and are capable of causing considerable morbidity and mortality in a number of mammalian species, including humans. However, in contrast to many other species and despite expression of functional virus entry receptors, mice are resistant to henipavirus infection. We report here the susceptibility of mice deleted for the type I interferon receptor (IFNAR-KO) to both HeV and NiV. Intraperitoneally infected mice developed fatal encephalitis, with pathology and immunohistochemical features similar to what was found in humans. Viral RNA was found in the majority of analyzed organs, and sublethally infected animals developed virus-specific neutralizing antibodies. Altogether, these results reveal IFNAR-KO mice as a new small animal model to study HeV and NiV pathogenesis, prophylaxis, and treatment and suggest the critical role of type I interferon signaling in the control of henipavirus infection.
Collapse
|
41
|
Ferraris O, Escuret V, Bouscambert M, Casalegno JS, Jacquot F, Raoul H, Caro V, Valette M, Lina B, Ottmann M. H1N1 influenza A virus neuraminidase modulates infectivity in mice. Antiviral Res 2012; 93:374-80. [PMID: 22321413 DOI: 10.1016/j.antiviral.2012.01.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2011] [Revised: 01/18/2012] [Accepted: 01/24/2012] [Indexed: 11/25/2022]
Abstract
In the 2years since the onset of the H1N1 2009 pandemic virus (H1N1pdm09), sporadic cases of oseltamivir-resistant viruses have been reported. We investigated the impact of oseltamivir-resistant neuraminidase from H1N1 Brisbane-like (seasonal) and H1N1pdm09 viruses on viral pathogenicity in mice. Reassortant viruses with the neuraminidase from seasonal H1N1 virus were obtained by co-infection of a H1N1pdm09 virus and an oseltamivir-resistant H1N1 Brisbane-like virus. Oseltamivir-resistant H1N1pdm09 viruses were also isolated from patients. After biochemical characterization, the pathogenicity of these viruses was assessed in a murine model. We confirmed a higher infectivity, in mice, of the H1N1pdm09 virus compared to seasonal viruses. Surprisingly, the oseltamivir-resistant H1N1pdm09 virus was more infectious than its sensitive counterpart. Moreover, the association of H1N1pdm09 hemagglutinin and an oseltamivir-resistant neuraminidase improved the infectivity of reassortant viruses in mice, regardless of the NA origin: seasonal (Brisbane-like) or pandemic strain. This study highlights the need to closely monitor the emergence of oseltamivir-resistant viruses.
Collapse
|
42
|
Reynard O, Reid SP, Page A, Mateo M, Alazard-Dany N, Raoul H, Basler CF, Volchkov VE. Unconventional secretion of Ebola virus matrix protein VP40. J Infect Dis 2011; 204 Suppl 3:S833-9. [PMID: 21987759 DOI: 10.1093/infdis/jir305] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
The Ebola virus matrix protein VP40 plays an essential role in virus assembly and budding. In this study we reveal that transient VP40 expression results in the release into the culture medium of substantial amounts of soluble monomeric VP40 in addition to the release of virus-like particles containing an oligomeric form of this protein as previously described. We show that VP40 secretion is endoplasmic reticulum/Golgi-independent and is not associated with cell death. Soluble VP40 was observed during Ebola virus infection of cells and was also found in the serum of virus-infected animals albeit in lower amounts. Unconventional secretion of VP40 may therefore play a role in Ebola virus pathogenicity.
Collapse
Affiliation(s)
- Olivier Reynard
- Filovirus Laboratory, Inserm U758, Human Virology Department, Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Reynard O, Nemirov K, Page A, Mateo M, Raoul H, Weissenhorn W, Volchkov VE. Conserved proline-rich region of Ebola virus matrix protein VP40 is essential for plasma membrane targeting and virus-like particle release. J Infect Dis 2011; 204 Suppl 3:S884-91. [PMID: 21987765 DOI: 10.1093/infdis/jir359] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The matrix protein VP40 is essential for Ebola virus (EBOV) and Marburg virus assembly and budding at the plasma membrane. In this study we have investigated the effect of single amino acid substitutions in a conserved proline-rich region of the EBOV VP40 located in the carboxy-terminal part of the protein. We demonstrate that substitutions within this region result in an alteration of intracellular VP40 localization and also cause a reduction or a complete block of virus-like particle budding, a benchmark of VP40 function. Furthermore, some mutated VP40s revealed an enhanced binding with cellular Sec24C, a part of the coat protein complex II (COPII) vesicular transport system. Analysis of the 3-dimensional structure of VP40 revealed the spatial proximity of the proline-rich region and an earlier identified site of interaction with Sec24C, thus allowing us to hypothesize that the altered intracellular localization of the VP40 mutants is a consequence of defects in their interaction with COPII-mediated vesicular transport.
Collapse
Affiliation(s)
- Olivier Reynard
- Filovirus Laboratory, INSERM U758, Human Virology Department, Claude Bernard Université Lyon 1, Ecole Normale Supérieure de Lyon, Lyon, France
| | | | | | | | | | | | | |
Collapse
|
44
|
Martinez MJ, Volchkova VA, Raoul H, Alazard-Dany N, Reynard O, Volchkov VE. Role of VP30 phosphorylation in the Ebola virus replication cycle. J Infect Dis 2011; 204 Suppl 3:S934-40. [PMID: 21987772 DOI: 10.1093/infdis/jir320] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Ebola virus (EBOV) transcription is dependent on the phosphoprotein VP30, a component of the viral nucleocapsid. VP30 is phosphorylated at 2 serine residue clusters located at the N-terminal part of the protein. In this report, we have investigated the role of VP30 phosphorylation in EBOV replication using a reverse genetics approach. In effect, recombinant EBOVs with the VP30 serine clusters substituted either by nonphosphorylatable alanines or phosphorylation-mimicking aspartates were generated and characterized. We show that in comparison to the wild-type EBOV the mutated viruses possess reduced infectivity. This difference is explained by alterations in the balance between the transcription and replication processes and appear to be associated with the state of VP30 phosphorylation. Here we propose a model in which dynamic phosphorylation of VP30 is an important mechanism to regulate the EBOV replication cycle.
Collapse
Affiliation(s)
- Miguel J Martinez
- INSERM U758, Human Virology Department, Université de Lyon, Claude Bernard University Lyon-1, Ecole Normale Supérieure de Lyon, Lyon, France
| | | | | | | | | | | |
Collapse
|
45
|
Reynard O, Mokhonov V, Mokhonova E, Leung J, Page A, Mateo M, Pyankova O, Georges-Courbot MC, Raoul H, Khromykh AA, Volchkov VE. Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. J Infect Dis 2011; 204 Suppl 3:S1060-5. [PMID: 21987742 DOI: 10.1093/infdis/jir347] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Pre- or postexposure treatments against the filoviral hemorrhagic fevers are currently not available for human use. We evaluated, in a guinea pig model, the immunogenic potential of Kunjin virus (KUN)-derived replicons as a vaccine candidate against Ebola virus (EBOV). Virus like particles (VLPs) containing KUN replicons expressing EBOV wild-type glycoprotein GP, membrane anchor-truncated GP (GP/Ctr), and mutated GP (D637L) with enhanced shedding capacity were generated and assayed for their protective efficacy. Immunization with KUN VLPs expressing full-length wild-type and D637L-mutated GPs but not membrane anchor-truncated GP induced dose-dependent protection against a challenge of a lethal dose of recombinant guinea pig-adapted EBOV. The surviving animals showed complete clearance of the virus. Our results demonstrate the potential for KUN replicon vectors as vaccine candidates against EBOV infection.
Collapse
Affiliation(s)
- O Reynard
- Filovirus Laboratory, INSERM U758, Human Virology Department, Claude Bernard University Lyon-1, Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Ippolito G, Nisii C, Di Caro A, Brown D, Gopal R, Hewson R, Lloyd G, Gunther S, Eickmann M, Mirazimi A, Koivula T, Georges Courbot MC, Raoul H, Capobianchi MR. European perspective of 2-person rule for biosafety level 4 laboratories. Emerg Infect Dis 2010; 15:1858. [PMID: 19891889 PMCID: PMC2857259 DOI: 10.3201/eid1511.091134] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
|
47
|
Gazin V, Kerdine S, Grillon G, Pallardy M, Raoul H. Uranium induces TNFα secretion and MAPK activation in a rat alveolar macrophage cell line. Toxicol Appl Pharmacol 2004; 194:49-59. [PMID: 14728979 DOI: 10.1016/j.taap.2003.08.016] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Uranium is a toxic heavy metal found mainly in the nuclear industry, but it is also used in the manufacturing of military munitions. Inhalation studies using animal models have demonstrated that long-term exposure to uranium can lead to the development of neoplasia and fibrosis at the pulmonary level. Because it has been demonstrated that such effects are often associated with inflammation, the effect of uranium on TNFalpha, IL-1beta, and IL-10 synthesis by macrophages was assessed in vitro using the NR8383 cell line. Our results show that a significant TNFalpha secretion was induced by uranium but not by other metals such as gadolinium. However, IL-1beta and IL-10 secretions were unaffected by uranium treatment. TNFalpha secretion was detectable since 50 microM of uranium and was maximal after 24 h of exposure. Determination of the mechanisms of uranium-induced TNFalpha production was assessed through the evaluation of protein kinases activation. Our results showed that uranium treatment induced c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK) activation. The use of pharmacological inhibitors suggested that both p38 MAPK and protein kinase C (PKC) participate in the signal transduction of uranium-induced TNFalpha secretion. The regulation of TNFalpha secretion involves TNFalpha mRNA accumulation at least through the stabilization of TNFalpha mRNA, but p38 MAPK did not appear to be involved in this stabilization. However, this observation does not exclude regulation of TNFalpha synthesis at the transcriptional level, which remains to be demonstrated. Taking together, these results suggest that uranium can induce TNFalpha secretion by macrophages, thus contributing to a better understanding of the pathological effect of uranium on the lung.
Collapse
Affiliation(s)
- Vincent Gazin
- Laboratoire de Radiotoxicologie, Commissariat à l'Energie Atomique, DSV/DRR, Bruyères le Châtel, France
| | | | | | | | | |
Collapse
|
48
|
Abstract
Macrophages are suspected to play a major role in human immunodeficiency virus (HIV) infection pathogenesis, not only by their contribution to virus dissemination and persistence in the host but also through the dysregulation of immune functions. The production of NO, a highly reactive free radical, is thought to act as an important component of the host immune response in several viral infections. The aim of this study was to evaluate the effects of HIV type 1 (HIV-1) Ba-L replication on inducible nitric oxide synthase (iNOS) mRNA expression in primary cultures of human monocyte-derived macrophages (MDM) and then examine the effects of NO production on the level of HIV-1 replication. Significant induction of the iNOS gene was observed in cultured MDM concomitantly with the peak of virus replication. However, this induction was not accompanied by a measurable production of NO, suggesting a weak synthesis of NO. Surprisingly, exposure to low concentrations of a NO-generating compound (sodium nitroprusside) and L-arginine, the natural substrate of iNOS, results in a significant increase in HIV replication. Accordingly, reduction of L-arginine bioavailability after addition of arginase to the medium significantly reduced HIV replication. The specific involvement of NO was further demonstrated by a dose-dependent inhibition of viral replication that was observed in infected macrophages exposed to N(G)-monomethyl L-arginine and N(G)-nitro-L-arginine methyl ester (L-NAME), two inhibitors of the iNOS. Moreover, an excess of L-arginine reversed the addition of L-NAME, confirming that an arginine-dependent mechanism is involved. Finally, inhibitory effects of hemoglobin which can trap free NO in culture supernatants and in biological fluids in vivo confirmed that endogenously produced NO could interfere with HIV replication in human macrophages.
Collapse
Affiliation(s)
- D Blond
- Service de Neurovirologie, Commissariat à l'Energie Atomique, DSV/DRM, CRSSA, Institut Paris-Sud sur les Cytokines, Fontenay aux Roses, France
| | | | | | | |
Collapse
|
49
|
Merat R, Raoul H, Leste-Lasserre T, Sonigo P, Pancino G. Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1. J Virol 1999; 73:5698-706. [PMID: 10364320 PMCID: PMC112629 DOI: 10.1128/jvi.73.7.5698-5706.1999] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Lentiviruses have in their transmembrane glycoprotein (TM) a highly immunogenic structure referred to as the principal immunodominant domain (PID). The PID forms a loop of 5 to 7 amino acids between two conserved cysteines. Previous studies showed that envelope (Env) glycoprotein functions of feline immunodeficiency virus (FIV) could be retained after extensive mutation of the PID loop sequence, in spite of its high conservation. In order to compare Env function in different lentiviruses, either random mutations were introduced in the PID loop sequence of human immunodeficiency virus type 1 (HIV-1) or the entire HIV-1 PID loop was replaced by the corresponding PID loop of FIV or simian immunodeficiency virus (SIV). In the macrophage-tropic HIV-1 ADA Env, mutations impaired the processing of the gp160 Env precursor, thereby abolishing viral infectivity. However, 6 of the 108 random Env mutants that were screened retained the capacity to induce cell membrane fusion. The SIV and FIV sequences and five random mutations were then introduced in the context of T-cell-line-adapted HIV-1 LAI which, although phenotypically distant from HIV-1 ADA, has an identical PID loop sequence. In contrast to the situation for HIV-1 ADA mutants, the cleavage of the Env precursor was unaffected in most HIV-1 LAI mutants. Such mutations, however, resulted in increased shedding of the gp120 surface glycoprotein (SU) from the gp41 TM. The HIV-1 LAI Env mutants showed high fusogenic efficiency. Three Env mutants retained the capacity to mediate virus entry in target cells, although less efficiently than the wild-type Env, and allowed the reconstitution of infectious molecular clones. These results indicated that in HIV-1, like FIV, the conserved PID sequence can be changed without impairing Env function. However, functional constraints on the PID of HIV-1 vary depending on the structural context of Env, presumably in relation to the role of the PID in the interaction of the SU and TM subunits and the stability of the Env complex.
Collapse
Affiliation(s)
- R Merat
- Génétique des Virus (ICGM-CNRS UPR0415), Institut Cochin de Génétique Moléculaire, 75014 Paris, France
| | | | | | | | | |
Collapse
|
50
|
Aillet F, Masutani H, Elbim C, Raoul H, Chêne L, Nugeyre MT, Paya C, Barré-Sinoussi F, Gougerot-Pocidalo MA, Israël N. Human immunodeficiency virus induces a dual regulation of Bcl-2, resulting in persistent infection of CD4(+) T- or monocytic cell lines. J Virol 1998; 72:9698-705. [PMID: 9811703 PMCID: PMC110479 DOI: 10.1128/jvi.72.12.9698-9705.1998] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
This work aims at characterizing the interplay between human immunodeficiency virus type 1 (HIV-1) and the antiapoptotic cellular protein Bcl-2 responsible for a persistent infection in lymphoblastoid T (J.Jhan) or monocytic (U937) cells. We report that the kinetics of Bcl-2 protein level during the establishment of a chronic infection is biphasic, characterized by a transient decrease followed by restoration to the initial level. The extent and duration of this transient decrease were inversely correlated with the basal level of Bcl-2 as shown by kinetics of Bcl-2 levels in J. Jhan or U937 clones exhibiting different levels of Bcl-2. Using these clones, we also showed that Bcl-2 downregulates HIV-1 replication. Therefore, the cells overexpressing Bcl-2 are characterized by a low viral burden which, in turn, has little effect on the level of this protein. The observed bipasic kinetics is the result of a dual regulation of Bcl-2 induced by HIV-1 infection itself: an upregulation at the transcriptional level of the bcl-2 gene concomitant with a downregulation at the protein level. Convergent data suggest that this downregulation is caused by the oxidative stress induced by the infection itself as shown by the associated modulations of glutathione and thioredoxin levels and by the prevention of these dysregulations by N-acetylcysteine. Altogether, these data indicate that infection first results in a decrease of Bcl-2, permitting an initial boost of replication. Then, as the synthesis at the transcriptional level proceeds, the replication is negatively controlled by Bcl-2 to reach a balance characterized by low virus production and a level of Bcl-2 compatible with cell survival. We suggest that the basal level of Bcl-2, together with infection-inducible transcription factors able to activate bcl-2 gene transcription, is a critical cellular determinant in the tendency toward an acute or a persistent infection.
Collapse
Affiliation(s)
- F Aillet
- Unité de Biologie des Rétrovirus, Institut Pasteur, 75724 Paris Cedex 15, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|